Heterocyclic Modulators of Lipid Synthesis

Abstract

Compounds are provided that are fatty acid synthesis modulators. The compounds can be used to treat diseases characterized by dysregulation of fatty acid synthase function by modulating the function and / or fatty acid synthase pathway. Methods for treating such diseases are provided, including viral infections such as hepatitis C infection, cancer, and metabolic disorders such as nonalcoholic steatohepatitis (NASH). [Selected Figure] Figure 1

Description

[Field of technology]

[0001] Cross-reference to related applications This application claims priority to and the benefit of U.S. Provisional Application No. 62 / 574,497 (filed October 19, 2017), and also prior-filed U.S. Provisional Application No. 61 / 450,561 (March 2011). US Provisional Application No. 61 / 508,611 (filed July 16, 2011) and US Provisional Application No. 61 / 585,642 (filed January 11, 2012). U.S. Patent Application No. 14 / 315,133 (filed June 25, 2014) (now abandoned) which is a continuation of U.S. Patent Application No. 13 / 415,660 (filed March 8, 2012) (now U.S. Patent No. 8,871,790) ), a continuation-in-part of U.S. Patent Application Serial No. 14 / 874,961 (filed October 5, 2015); 3), U.S. Provisional Application No. 61 / 698,511 (filed September 7, 2012), U.S. Provisional Application No. 61 / 699,819 (filed September 11, 2012) and U.S. Provisional Application No. 61 / U.S. patent application Ser. No. 15 / 201,824 (filed July 5, 2016), which is a divisional application of U.S. Patent Application No. 15 / 201,824 (filed July 5, 2016); and a previously filed U.S. provisional application U.S. National Phase of PCT / US2015 / 010459 (filed January 7, 2015) filed under 35 U.S.C. 371 claiming priority to No. 61 / 924,520 (filed January 7, 2014) Priority to U.S. patent application Ser. Claim profit.

[0002] The entire contents of each of these applications are hereby incorporated by reference in their entirety for all purposes.

[0003] The present disclosure relates generally to heterocyclic modulators of lipid synthesis and methods of use thereof. The present heterocyclic modulators of lipid synthesis can be used to treat disorders characterized by dysregulation of fatty acid synthase function in a subject by modulating the fatty acid synthase pathway and / or fatty acid synthase function. [Background technology]

[0004] Viral diseases are a health concern that threatens a large portion of the human population. Some of the characteristics associated with viral infections that concern medical professionals include their highly contagious characteristics (eg, HIV, SARS, etc.) and high mutability. Some viruses are also oncogenic (eg HPV, EBV and HBV). Viruses are one of the structurally simplest organisms, but are also considered to be one of the most difficult to control and present a threatening challenge to antiviral drug R&D.

[0005] To date, several antiviral drugs, such as amantadine and oseltamivir for influenza, acyclovir for HSV-associated infections, ganciclovir for CMV infections, and co-formulated drugs for the treatment of AIDS (efavirenz , emtricitabine, and tenofovir (tonfovir disoproxifumarate) have been widely used in patients. These drugs have various undesirable neurological, metabolic and immunological side effects. Therefore, the development of novel antiviral therapies has become the focus of medical and pharmaceutical research and development.

[0006] Infection with hepatitis C virus (HCV) is a serious health problem. It is estimated that 170 million people worldwide are chronically infected with HCV. HCV infection can lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. Chronic HCV infection is therefore the leading cause of liver-related premature mortality worldwide.

[0007] The current standard therapeutic treatment regimen for HCV infection includes combination therapy with interferon-alpha and ribavirin, often supplemented with direct-acting protease inhibitors (telaprevir or boceprevir). This procedure is cumbersome and can have severe and debilitating side effects. For this reason, many patients are not treated early in the disease. Additionally, some patient populations do not permanently respond to treatment. New effective methods of treating HCV infection are urgently needed.

[0008] The main therapeutic approaches currently used to treat cancer include surgical removal of the primary tumor, tumor irradiation, and parenteral application of anti-mitotic cytotoxic agents. Unfortunately, only a relatively small proportion of cancer patients have tumors that "addict" a particular pathway and therefore can be treated with newer targeted agents. The continued dominance of these older therapies reflects the lack of improved survival for most cancers. In addition to limited clinical success, classical therapy is associated with strong side effects. Both radiation- and cytotoxic-based therapies result in the destruction of rapidly dividing hematopoietic and intestinal epithelial cells, leading to immune dysfunction, anemia, and nutrient malabsorption. Surgical intervention often results in the release of tumor cells into the circulatory or lymphatic system, from which metastatic tumors can later be established. Methods for improved cancer treatment are needed.

[0009] Non-alcoholic liver disease (NAFLD), a condition in which the liver contains more than 5% fat by weight and is not attributable to alcohol consumption, currently affects approximately 20-30% of the population in the United States and Western Europe in general. It is associated with a significantly elevated risk of morbidity that extends beyond the liver to cardiovascular disease (i.e. carotid atherosclerotic plaques and endothelial dysfunction), chronic kidney disease and malignancies. Obesity and metabolic syndrome are two major risk factors for NAFLD characterized by imbalances in energy utilization and storage. This imbalance results in dysregulation of metabolic pathways and inflammatory responses, further leading to changes leading to liver damage and complications. Along with the progression of metabolic syndrome, NAFLD leads to more advanced liver disease, beginning with nonalcoholic steatohepatitis (NASH), which can then progress to serious liver disease, including cirrhosis and hepatocellular carcinoma.

[0010] Subjects with metabolic syndrome and NAFLD have increased synthesis of fatty acids in the liver, a pathway also called de novo lipogenesis (DNL) in the liver (Donnelly, K.L, et.al., “Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease,”J.Clin.Invest.115(5).2005,1343-51;Lambert,J.E,et.al.,“Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease, “Ygast 146(3).2014, 726-35). The DNL pathway not only produces fatty acids that contribute to elevated hepatic stores of triglycerides, but also because the fatty acids produced are saturated fatty acid species, primarily palmitic acid, leading to signaling events that increase hepatitis. (Wei, Y., “Saturated Fatty Acids Induce Endoplasmic Reticulum Stress and Apoptosis Independently of Ceramide in Liver Cells,” Am. J. Physio. Endocrinol. Metab.291(2):2006, E275-81; Kakazu , E., et al., “Hepatocytes Release Ceramide-rich Proinflammatory Extracellular Vesicles in an IRE1alpha dependent manner,” Abstract 58. AASLD- The Liver Meeting, San Francisco, CA, USA, 13-17, November, 2015). One of the key enzymes in the DNL pathway is fatty acid synthase (FASN), which is only involved in synthesizing palmitate. DNL is therefore an important pathway for therapeutic intervention to alleviate the effects associated with metabolic syndrome and NAFLD. Inhibition of FASN is a treatment for a wide range of diseases, including cancer, viral diseases, metabolic diseases, NAFLD, NASH and inflammatory diseases (i.e. rheumatoid arthritis, gout, pulmonary fibrosis, COPD, IBD and transplant rejection). It may become law. In addition, FASN inhibition may have therapeutic benefits in cardiovascular disease, type II diabetes and metabolic syndrome. Successful treatment of these diseases remains an unmet need. Although there are treatments available for diabetes and cardiovascular disease, there are currently no drugs approved for the treatment of metabolic syndrome, NAFLD or NASH. Therefore, new and potent FASN small molecule inhibitors are needed to treat these diseases. [Prior art documents] [Non-Patent Literature]

[0011] [Non-Patent Document 1] Donnelly, K.L, et.al., “Sources of Fatty Acids Stored in Liver and Secreted via Lipoproteins in Patients with Nonalcoholic Fatty Liver Disease,” J.Clin.Invest.115(5).2005, 1343-51 [Non-Patent Document 2] Lambert,J.E,et.al.,“Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals with Nonalcoholic Fatty Liver Disease,”Ygast 146(3).2014,726-35 [Non-Patent Document 3] Wei, Y., “Saturated Fatty Acids Induce Endoplasmic Reticulum Stress and Apoptosis Independently of Ceramide in Liver Cells,” Am. J. Physio. Endocrinol. Metab.291(2):2006, E275-81 [Non-Patent Document 4] Kakazu,E.,et al.,“Hepatocytes Release Ceramide-rich Proinflammatory Extracellular Vesicles in an IRE1alpha dependent manner,”Abstract 58.AASLD- The Liver Meeting,San Francisco,CA,USA,13-17,November,2015 [Outline of the invention] [Means for solving the problem]

[0012] The present disclosure addresses deficiencies in antiviral and anticancer treatments by providing novel heterocyclic modulators of lipid synthesis with improved antiviral and anticancer activity.

[0013] In various aspects, the present disclosure provides compounds of structure (I): [Chemical 1] (I) (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; A is CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino; R. 17 and R 18 are each independently hydrogen or alkyl, or optionally linked together to form a bond; n is 1 or 2; m is 0 or 1) or a pharmaceutically acceptable salt thereof.

[0014] In various aspects, the present disclosure provides compounds of structure (II): [Chemical 2] (II) (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; L and D are each independently C or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino; R. 17 and R 18 are each independently hydrogen or alkyl, or optionally linked together to form a bond; n is 1 or 2; m is 0 or 1) or a pharmaceutically acceptable salt thereof.

[0015] In various aspects, the present disclosure provides compounds of structure (III): [Chemical 3] (III) (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; Q is C or N; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 alkoxy or when Q is N, then R 3 is nonexistent; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino; R. 17 and R 18 are each independently hydrogen or alkyl, or optionally linked together to form a bond; R. 19 is aryl, heteroaryl, cycloalkyl or heterocyclyl; n is 0, 1 or 2; m is 0 or 1) or a pharmaceutically acceptable salt thereof.

[0016] In various aspects, the present disclosure provides compounds of structure (IV-A), (IV-B) or (IV-C): [Chemical 4] (In the formula, L. 1 , L 2 , L 3 , L 4 and A are each independently CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 alkoxy or C 1〜6 is an alkyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 21 and R 22 are each independently hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; R. 23 is hydrogen, -N(R 13 )(R 14 ), C 1 ~ 6 Alkyl, C1 ~ 6 is alkoxy and L 1 is non-existent if is N, or R 23 and R 24 are linked together with the atoms to which they are attached to form a heterocyclyl, heteroaryl or cycloalkyl; R. 24 is hydrogen, -N(R 13 )(R 14 ), C 1 ~ 6 Alkyl, C 1 ~ 6 alkoxy, -(C 1 ~ 6 alkoxy)(heterocyclyl), heterocyclyl, or R 23 and R 24 are linked together with the atoms to which they are attached to form a heterocyclyl, heteroaryl or cycloalkyl; R. 26 is hydrogen, heteroaryl, heterocyclyl, -N(R 13 )(R 14 ), or -S(=O) 2 R. 20 is; R. 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 25 is hydrogen, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 15 and R 16 are each independently hydrogen, C 1〜6 Alkyl, C 1〜6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl or alkylamino) or a pharmaceutically acceptable salt thereof.

[0017] In various aspects, the present disclosure provides compounds of structure (V): [Chemical 5] (V) (In the formula, L. 7 is N or O, where L 7 is O, then R 30 is nonexistent; A is CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 alkoxy or C 1〜6 is an alkyl; R. 3 is a halo, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 21 and R 22 are each independently hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; R. 29 and R 30 are each independently hydrogen, C 1〜6 Alkyl, C 1〜6 Alkoxy, hydroxyalkyl, heteroaryl, heterocyclyl, -N(R 15 R. 16 ), -C(=O)R 46 , -R 48 C(=O)R 47 or R 29 and R 30 are joined together with the atoms to which they are attached to form a heteroaryl or heterocyclyl, where R 30 is L 7 is nonexistent if is O; R. 46 and R 47 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 48 is alkyl or absent; R. 31 is hydrogen, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl or alkylamino; v is 0 or 1) or a pharmaceutically acceptable salt thereof.

[0018] In various aspects, the present disclosure provides compounds of structure (VI-A) or (VI-B): [Chemical 6] (In the formula, L. 13 , L 14 , L 15 and A are each independently CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 alkoxy or C 1〜6 is an alkyl; R. 3 is a halo, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 21 and R 22 are each independently hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; R. 34 is hydrogen, C 1〜6 Alkyl, C 1〜6 Alkoxy, Cycloalkyl, Hydroxyl, Hydroxyalkyl, Aryl, Heterocyclyl, Heteroaryl, Alkylamino, CF 3 , -OCF 3 , -S(=O) 2 R. 20 , or -N(R 15 R. 16 ) and; R. 35 is hydrogen, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 36 is hydrogen, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 15 R. 16 ), heterocyclyl or heteroaryl; R. 13 and R 14 are each independently hydrogen, C 1〜6Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 Alkyl, C 1〜6 alkoxy, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl or alkylamino) or a pharmaceutically acceptable salt thereof.

[0019] In various aspects, the present disclosure provides compounds of structure (VI-J): [Chemical 7] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof.

[0020] In some embodiments of Structures (VI-J), R 3 is H or halogen.

[0021] In some embodiments of Structures (VI-J), R 1 is halogen, -CN or C 1 ~C 2 is haloalkyl.

[0022] In some embodiments of Structures (VI-J), R 22 is C 1 ~C 2 is alkyl.

[0023] In some embodiments of Structures (VI-J), R 21 is cyclobutyl and R 22 is C 1 ~C 2 is alkyl.

[0024] In some embodiments of Structures (VI-J), R 21 is cyclobutyl.

[0025] In some embodiments of Structures (VI-J), R 3 is H or F.

[0026] In some embodiments of Structures (VI-J), R 1 is -CN.

[0027] In some embodiments of Structures (VI-J), R 1 is -CF 3 is.

[0028] In some embodiments of Structures (VI-J), R 22 is H, methyl or ethyl.

[0029] In some embodiments of Structures (VI-J), R 22 is H.

[0030] In some embodiments of Structures (VI-J), R 22 is methyl.

[0031] In some embodiments of Structures (VI-J), R 35 is -C(O)-NHR 351 is.

[0032] In some embodiments of Structures (VI-J), R 351 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2H-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[0033] In some embodiments of Structures (VI-J), R 351 is (R)-(tetrahydrofuran-2-yl)methyl or (S)-(tetrahydrofuran-2-yl)methyl.

[0034] In some embodiments of Structures (VI-J), R 1 is -CN and each R 2 is hydrogen and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is H and R 35 is -C(O)-NHR 351 , where R 351 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2H-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[0035] In some embodiments of Structures (VI-J), R 35 is -C(O)-O-R 351 is.

[0036] In some embodiments of Structures (VI-J), R 351 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2H-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[0037] In some embodiments of Structures (VI-J), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is H and R 35 is -C(O)-O-R 351 , where R 351 is isopropyl, isobutyl, (R)-3-tetrahydrofuranyl, (S)-3-tetrahydrofuranyl, (R)-(tetrahydrofuran-2-yl)methyl, (S)-(tetrahydrofuran-2-yl)methyl, (R)-tetrahydro-2H-pyran-3-yl or (S)-tetrahydro-2H-pyran-3-yl.

[0038] In some embodiments of Structures (VI-J), R 351 is (R)-3-tetrahydrofuranyl or (S)-3-tetrahydrofuranyl.

[0039] In some embodiments of Structures (VI-J), the compound is [Chemical 8] having a structure selected from the group consisting of

[0040] In various aspects, the present disclosure provides compounds of structure (VII-A) or (VII-B): [Chemical 9] (In the formula, L. 16 is C or N, where L 16 is N, then R 41 is nonexistent; L. 17 , L 18 and A are each independently CH or N; R. 1 is hydrogen, cyano, halo, C1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 alkoxy or C 1〜6 is an alkyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 21 and R 22 are each independently hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; R. 40 , R 42 and R 43 are each independently hydrogen, C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 , -C(=O)R, hydroxyalkyl, hydroxyl, -N(R 13 R. 14 ), or R 41 and R 42 are linked together with the atoms to which they are attached to form a heteroaryl or heterocyclyl; R. 41 is hydrogen, C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 , -C(=O)R, hydroxyalkyl, hydroxyl, -N(R 13 R. 14 ) and R 41 is L 16 is non-existent if is N, or R 41 and R 42 are linked together with the atoms to which they are attached to form a heteroaryl or heterocyclyl; R is hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, -N(R 15 R. 16 ) or -S(=O) 2 R. 20 is; R. 39 is hydrogen, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl or alkylamino) or a pharmaceutically acceptable salt thereof.

[0041] In various aspects, the present disclosure provides compounds of structure (VIII-A), (VIII-B) or (VIII-C): [Chemical 10] (In the formula, L. 19 and A are each independently CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 alkoxy or C 1〜6 is an alkyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 21 and R 22 are each independently hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; R. 39 is hydrogen, C 1〜6 alkyl or C 1〜6 is alkoxy; R. 44 and R 45 are each independently hydrogen, C 1〜6 Alkyl, C 1〜6 alkoxy, cycloalkyl, hydroxyalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, -S(=O) 2 R. 20 , -C(=O)R, or -N(R 13 R. 14 ) and; R. 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl or alkylamino) or a pharmaceutically acceptable salt thereof.

[0042] In various embodiments, a compound of structure (IX): [Chemical 11] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof.

[0043] In some embodiments of structure (IX), R 24 is C 1 ~C 4 straight or branched chain alkyl or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl) where t is 0 or 1.

[0044] In some embodiments of structure (IX), R 21 is halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 Cycloalkyl (in this case C 3 ~C 5 Cycloalkyl optionally includes an oxygen or nitrogen heteroatom), -S(O) u -(C 1 ~C 4 straight or branched chain alkyl) (where u is 0 or 2), or -S(O) u -(C 3 ~C 5 cycloalkyl) (where u is 0 or 2).

[0045] In some embodiments of structure (IX), R 3 is H or halogen.

[0046] In some embodiments of Structure (IX), R 1 is halogen, -CN or C 1 ~C 2 is haloalkyl.

[0047] In some embodiments of structure (IX), L 1 and L 2 are both N.

[0048] In some embodiments of structure (IX), R 21 is C 1 ~C 2 alkyl or C 3 ~C 5 cycloalkyl and R 22 is C 1 ~C 2 is alkyl.

[0049] In some embodiments of structure (IX), R 21 is C 3 ~C 5 cycloalkyl and R 22 is C 1 ~C 2 is alkyl.

[0050] In some embodiments of structure (IX), R 24 is -(C 1 ~C 2 alkyl) t -O-(C 1 ~C 2 alkyl) where t is 0 or 1.

[0051] In some embodiments of structure (IX), R 21 is C 3 ~C 5 cycloalkyl and R 22 is C 1 ~C 2 is alkyl and R 24 is C 1 ~C 2 is alkyl.

[0052] In some embodiments of structure (IX), R 21 is cyclobutyl and R 22 is C 1 ~C 2 is alkyl and R 24 is C 1 ~C 2 is alkyl.

[0053] In some embodiments of structure (IX), R 21 is cyclobutyl.

[0054] In some embodiments of structure (IX), R 3 is H or F.

[0055] In some embodiments of structure (IX), R 1 is -CN.

[0056] In some embodiments of structure (IX), R 1 is -CF 3 is.

[0057] In some embodiments of structure (IX), R 22 is H, methyl or ethyl.

[0058] In some embodiments of structure (IX), R 22 is H.

[0059] In some embodiments of structure (IX), R 22 is methyl.

[0060] In some embodiments of structure (IX), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is methyl and L 1 and L 2 is N and R 24 is methyl, ethyl, hydroxymethyl, methoxymethyl, 2-methoxyethyl.

[0061] In some embodiments of structure (IX), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is methyl and L 1 and L 2 is N and R 24 is methoxy or ethoxy.

[0062] In some embodiments of structure (IX), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is methyl and L 1 is CH and L 2 is N and R 24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[0063] In some embodiments of structure (IX), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is methyl and L 1 is N and L 2 is CH and R 24 is methyl, ethyl, hydroxymethyl, methoxymethyl, or 2-methoxyethyl.

[0064] In some embodiments of structure (IX), the compound is [Chemical 12] having a structure selected from the group consisting of

[0065] In various embodiments, compounds of structure (X): [Chemical 13] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof.

[0066] In some embodiments of structure (X), R 21 is halogen, C 1 ~C 4 straight or branched chain alkyl or C 3 ~C 5 is cycloalkyl.

[0067] In some embodiments of structure (X), R 3 is H or halogen.

[0068] In some embodiments of structure (X), R 1 is -CN or C 1 ~C 2 is haloalkyl.

[0069] In some embodiments of structure (X), R 3 is H or F.

[0070] In some embodiments of structure (X), R 1 is -CN.

[0071] In some embodiments of structure (X), R 1 is -CF 3 is.

[0072] In some embodiments of Structure (X), n is 1.

[0073] In some embodiments of Structure (X), n is 2.

[0074] In some embodiments of Structure (X), m is 1.

[0075] In some embodiments of Structure (X), m is 2.

[0076] In some embodiments of structure (X), R 21 is C 1 ~C 2 alkyl or C 3 ~C 5 cycloalkyl and R 22 is C 1 ~C 2 is alkyl.

[0077] In some embodiments of structure (X), R 21 is C 3 ~C 5 cycloalkyl and R 22 is C 1 ~C 2 is alkyl.

[0078] In some embodiments of structure (X), n is 2, m is 1, and L 3 is -N-C(O)-O-(C 1 ~C 2 alkyl).

[0079] In some embodiments of structure (X), L 3 is NR 50 and R 50 is C 1 ~C 2 is alkyl and R 21 is cyclobutyl and R 22 is H or methyl and R 3 is H and R 1 is -CN, m is 2, and n is 1 or 2.

[0080] In some embodiments of structure (X), n is 2, m is 1, and L 3 is O and s is 0.

[0081] In some embodiments of structure (X), R 22 is H, methyl or ethyl.

[0082] In some embodiments of structure (X), R 22 is methyl.

[0083] In some embodiments of structure (X), R 22 is H.

[0084] In some embodiments of structure (X), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C4 cycloalkyl and R 22 is methyl, n is 2, L 3 is NR 50 , where R 50 is methyl or ethyl.

[0085] In some embodiments of structure (X), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is C 3 ~C 4 cycloalkyl and R 22 is methyl, n is 2, L 3 is O.

[0086] In some embodiments of structure (X), the compound is [Chemical 14] having a structure selected from the group consisting of

[0087] In various embodiments, a compound of structure (XI): [Chemical 15] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

[0088] In some embodiments of structure (XI), R 3 is H or halogen.

[0089] In some embodiments of structure (XI), R 1 is halogen, -CN or C 1 ~C 2 is haloalkyl.

[0090] In some embodiments of structure (XI), R 21 is C 3 ~C 4 cycloalkyl and R 22 is C 1 ~C 2 is alkyl.

[0091] In some embodiments of structure (XI), R 21 is cyclobutyl and R 22 is C 1 ~C 2 is alkyl.

[0092] In some embodiments of structure (XI), R 21 is cyclobutyl.

[0093] In some embodiments of structure (XI), R 3 is H or F.

[0094] In some embodiments of structure (XI), R 1 is -CN.

[0095] In some embodiments of structure (XI), R 1 is -CF 3 is.

[0096] In some embodiments of structure (XI), R 22 is H, methyl or ethyl.

[0097] In some embodiments of structure (XI), R 22 is H.

[0098] In some embodiments of structure (XI), R 22 is methyl.

[0099] In some embodiments of structure (XI), R 1 is -CN and each R 2 is H and R 3 is H or F and R 21 is cyclobutyl and R 22 is methyl and R 351 is methyl or ethyl.

[0100] In some embodiments of structure (XI), the compound is [Chemical 16] as well as [Chemical 17] having a structure selected from the group consisting of

[0101] In various embodiments, the present disclosure provides structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or A pharmaceutical composition is provided comprising any one of the compounds of (XI) and a pharmaceutically acceptable carrier, excipient or diluent.

[0102] In various aspects, the present disclosure provides methods of treating a condition characterized by dysregulation of fatty acid synthase function in a subject, comprising administering to a subject in need of such treatment structures (I), (II), (III) ), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI). , to provide a method. In various embodiments, the condition characterized by dysregulation of fatty acid synthase function is viral infection or cancer. In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI) Any one of the compounds is used in combination with one or more additional antiviral treatments to treat viral infections. In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) or (XI) Any one of the compounds is used in combination with one or more additional cancer treating agents to treat cancer. In various embodiments, the viral infection is hepatitis C.

[0103] In various aspects, the present disclosure provides a method of treating fatty liver disease in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 18] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 19] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 20] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 21] (XII) (In the formula, L-Ar is [Chemical 22] , [Chemical 23] or [Chemical 24] is; Ar is [Chemical 25] , [Chemical 26] , [Chemical 27] , [Chemical 28] or [Chemical 29] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 30] (XIII) (In the formula, L-Ar is [Chemical 31] , [Chemical 32] or [Chemical 33] is; Ar is [Chemical 34] , [Chemical 35] , [Chemical 36] , [Chemical 37] or [Chemical 38] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 39] (XIV) (In the formula, L-Ar is [Chemical 40] , [Chemical 41] or [Chemical 42] is; Ar is [Chemical 43] , [Chemical 44] , [Chemical 45] , [Chemical 46] or [Chemical 47] with the proviso that L-Ar is [Chemical 48] when Ar is [Chemical 49] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R.21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 50] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 51] , [Chemical 52] or [Chemical 53] is; Ar is [Chemical 54] , [Chemical 55] , [Chemical 56] , [Chemical 57] or [Chemical 58] with the proviso that L-Ar is [Chemical 59] when Ar is [Chemical 60] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 61] (XVI) (In the formula, L-Ar is [Chemical 62] , [Chemical 63] or [Chemical 64] is; Ar is [Chemical 65] , [Chemical 66] , [Chemical 67] , [Chemical 68] or [Chemical 69] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 70] (XVII) (In the formula, L-Ar is [Chemical 71] , [Chemical 72] or [Chemical 73] is; Ar is [Chemical 74] , [Chemical 75] , [Chemical 76] , [Chemical 77] or [Chemical 78] with the proviso that L-Ar is [Chemical 79] when Ar is [Chemical 80] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 81] (XVIII) (In the formula, L-Ar is [Chemical 82] , [Chemical 83] or [Chemical 84] is; Ar is [Chemical 85] , [Chemical 86] , [Chemical 87] , [Chemical 88] or [Chemical 89] with the proviso that L-Ar is [Chemical 90] when Ar is [Chemical 91] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 92] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 93] , [Chemical 94] , [Chemical 95] , [Chemical 96] or [Chemical 97] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 98] (XX) (In the formula, L-Ar is [Chemical 99] , [Chemical 100] or [Chemical 101] is; Ar is [Chemical 102] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 103] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0104] In various aspects, the present disclosure provides a method of treating nonalcoholic steatohepatitis (NASH) in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 104] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 105] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 106] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 107] (XII) (In the formula, L-Ar is [Chemical 108] , [Chemical 109] or [Chemical 110] is; Ar is [Chemical 111] , [Chemical 112] , [Chemical 113] , [Chemical 114] or [Chemical 115] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 116] (XIII) (In the formula, L-Ar is [Chemical 117] , [Chemical 118] or [Chemical 119] is; Ar is [Chemical 120] , [Chemical 121] , [Chemical 122] , [Chemical 123] or [Chemical 124] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 125] (XIV) (In the formula, L-Ar is [Chemical 126] , [Chemical 127] or [Chemical 128] is; Ar is [Chemical 129] , [Chemical 130] , [Chemical 131] , [Chemical 132] or [Chemical 133] with the proviso that L-Ar is [Chemical 134] when Ar is [Chemical 135] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 136] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 137] , [Chemical 138] or [Chemical 139] is; Ar is [Chemical 140] , [Chemical 141] , [Chemical 142] , [Chemical 143] or [Chemical 144] with the proviso that L-Ar is [Chemical 145] when Ar is [Chemical 146] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 147] (XVI) (In the formula, L-Ar is [Chemical 148] , [Chemical 149] or [Chemical 150] is; Ar is [Chemical 151] , [Chemical 152] , [Chemical 153] , [Chemical 154] or [Chemical 155] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 156] (XVII) (In the formula, L-Ar is [Chemical 157] , [Chemical 158] or [Chemical 159] is; Ar is [Chemical 160] , [Chemical 161] , [Chemical 162] , [Chemical 163] or [Chemical 164] with the proviso that L-Ar is [Chemical 165] when Ar is [Chemical 166] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 167] (XVIII) (In the formula, L-Ar is [Chemical 168] , [Chemical 169] or [Chemical 170] is; Ar is [Chemical 171] , [Chemical 172] , [Chemical 173] , [Chemical 174] or [Chemical 175] with the proviso that L-Ar is [Chemical 176] when Ar is [Chemical 177] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 178] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 179] , [Chemical 180] , [Chemical 181] , [Chemical 182] or [Chemical 183] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 184] (XX) (In the formula, L-Ar is [Chemical 185] , [Chemical 186] or [Chemical 187] is; Ar is [Chemical 188] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 189] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0105] In various aspects, the present disclosure provides a method of treating nonalcoholic fatty liver disease (NAFLD) in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 190] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 191] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 192] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 193] (XII) (In the formula, L-Ar is [Chemical 194] , [Chemical 195] or [Chemical 196] is; Ar is [Chemical 197] , [Chemical 198] , [Chemical 199] , [Chemical 200] or [Chemical 201] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 202] (XIII) (In the formula, L-Ar is [Chemical 203] , [Chemical 204] or [Chemical 205] is; Ar is [Chemical 206] , [Chemical 207] , [Chemical 208] , [Chemical 209] or [Chemical 210] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 211] (XIV) (In the formula, L-Ar is [Chemical 212] , [Chemical 213] or [Chemical 214] is; Ar is [Chemical 215] , [Chemical 216] , [Chemical 217] , [Chemical 218] or [Chemical 219] with the proviso that L-Ar is [Chemical 220] when Ar is [Chemical 221] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 222] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 223] , [Chemical 224] or [Chemical 225] is; Ar is [Chemical 226] , [Chemical 227] , [Chemical 228] , [Chemical 229] or [Chemical 230] with the proviso that L-Ar is [Chemical 231] when Ar is [Chemical 232] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 233] (XVI) (In the formula, L-Ar is [Chemical 234] , [Chemical 235] or [Chemical 236] is; Ar is [Chemical 237] , [Chemical 238] , [Chemical 239] , [Chemical 240] or [Chemical 241] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 242] (XVII) (In the formula, L-Ar is [Chemical 243] , [Chemical 244] or [Chemical 245] is; Ar is [Chemical 246] , [Chemical 247] , [Chemical 248] , [Chemical 249] or [Chemical 250] with the proviso that L-Ar is [Chemical 251] when Ar is [Chemical 252] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 253] (XVIII) (In the formula, L-Ar is [Chemical 254] , [Chemical 255] or [Chemical 256] is; Ar is [Chemical 257] , [Chemical 258] , [Chemical 259] , [Chemical 260] or [Chemical 261] with the proviso that L-Ar is [Chemical 262] when Ar is [Chemical 263] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 264] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 265] , [Chemical 266] , [Chemical 267] , [Chemical 268] or [Chemical 269] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 270] (XX) (In the formula, L-Ar is [Chemical 271] , [Chemical 272] or [Chemical 273] is; Ar is [Chemical 274] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 275] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0106] In various aspects, the present disclosure provides a method of treating metabolic syndrome in a subject in need thereof comprising: (a) Formula (IX) [Chemical 276] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 277] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 278] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 279] (XII) (In the formula, L-Ar is [Chemical 280] , [Chemical 281] or [Chemical 282] is; Ar is [Chemical 283] , [Chemical 284] , [Chemical 285] , [Chemical 286] or [Chemical 287] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 288] (XIII) (In the formula, L-Ar is [Chemical 289] , [Chemical 290] or [Chemical 291] is; Ar is [Chemical 292] , [Chemical 293] , [Chemical 294] , [Chemical 295] or [Chemical 296] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 297] (XIV) (In the formula, L-Ar is [Chemical 298] , [Chemical 299] or [Chemical 300] is; Ar is [Chemical 301] , [Chemical 302] , [Chemical 303] , [Chemical 304] or [Chemical 305] with the proviso that L-Ar is [Chemical 306] when Ar is [Chemical 307] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 308] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 309] , [Chemical 310] or [Chemical 311] is; Ar is [Chemical 312] , [Chemical 313] , [Chemical 314] , [Chemical 315] or [Chemical 316] with the proviso that L-Ar is [Chemical 317] when Ar is [Chemical 318] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 319] (XVI) (In the formula, L-Ar is [Chemical 320] , [Chemical 321] or [Chemical 322] is; Ar is [Chemical 323] , [Chemical 324] , [Chemical 325] , [Chemical 326] or [Chemical 327] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 328] (XVII) (In the formula, L-Ar is [Chemical 329] , [Chemical 330] or [Chemical 331] is; Ar is [Chemical 332] , [Chemical 333] , [Chemical 334] , [Chemical 335] or [Chemical 336] with the proviso that L-Ar is [Chemical 337] when Ar is [Chemical 338] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl); or a pharmaceutically acceptable salt thereof or (j) Formula (XVIII): [Chemical 339] (XVIII) (In the formula, L-Ar is [Chemical 340] , [Chemical 341] or [Chemical 342] is; Ar is [Chemical 343] , [Chemical 344] , [Chemical 345] , [Chemical 346] or [Chemical 347] with the proviso that L-Ar is [Chemical 348] when Ar is [Chemical 349] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 350] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 351] , [Chemical 352] , [Chemical 353] , [Chemical 354] or [Chemical 355] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 356] (XX) (In the formula, L-Ar is [Chemical 357] , [Chemical 358] or [Chemical 359] is; Ar is [Chemical 360] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 361] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0107] In various aspects, the present disclosure provides a method of treating liver cirrhosis in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 362] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 363] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 364] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 365] (XII) (In the formula, L-Ar is [Chemical 366] , [Chemical 367] or [Chemical 368] is; Ar is [Chemical 369] , [Chemical 370] , [Chemical 371] , [Chemical 372] or [Chemical 373] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 374] (XIII) (In the formula, L-Ar is [Chemical 375] , [Chemical 376] or [Chemical 377] is; Ar is [Chemical 378] , [Chemical 379] , [Chemical 380] , [Chemical 381] or [Chemical 382] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 383] (XIV) (In the formula, L-Ar is [Chemical 384] , [Chemical 385] or [Chemical 386] is; Ar is [Chemical 387] , [Chemical 388] , [Chemical 389] , [Chemical 390] or [Chemical 391] with the proviso that L-Ar is [Chemical 392] when Ar is [Chemical 393] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 394] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 395] , [Chemical 396] or [Chemical 397] is; Ar is [Chemical 398] , [Chemical 399] , [Chemical 400] , [Chemical 401] or [Chemical 402] with the proviso that L-Ar is [Chemical 403] when Ar is [Chemical 404] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 405] (XVI) (In the formula, L-Ar is [Chemical 406] , [Chemical 407] or [Chemical 408] is; Ar is [Chemical 409] , [Chemical 410] , [Chemical 411] , [Chemical 412] or [Chemical 413] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 414] (XVII) (In the formula, L-Ar is [Chemical 415] , [Chemical 416] or [Chemical 417] is; Ar is [Chemical 418] , [Chemical 419] , [Chemical 420] , [Chemical 421] or [Chemical 422] with the proviso that L-Ar is [Chemical 423] when Ar is [Chemical 424] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 425] (XVIII) (In the formula, L-Ar is [Chemical 426] , [Chemical 427] or [Chemical 428] is; Ar is [Chemical 429] , [Chemical 430] , [Chemical 431] , [Chemical 432] or [Chemical 433] with the proviso that L-Ar is [Chemical 434] when Ar is [Chemical 435] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 436] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 437] , [Chemical 438] , [Chemical 439] , [Chemical 440] or [Chemical 441] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 442] (XX) (In the formula, L-Ar is [Chemical 443] , [Chemical 444] or [Chemical 445] is; Ar is [Chemical 446] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 447] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0108] In various aspects, the present disclosure provides a method of treating liver fibrosis in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 448] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 449] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 450] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 451] (XII) (In the formula, L-Ar is [Chemical 452] , [Chemical 453] or [Chemical 454] is; Ar is [Chemical 455] , [Chemical 456] , [Chemical 457] , [Chemical 458] or [Chemical 459] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 460] (XIII) (In the formula, L-Ar is [Chemical 461] , [Chemical 462] or [Chemical 463] is; Ar is [Chemical 464] , [Chemical 465] , [Chemical 466] , [Chemical 467] or [Chemical 468] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R.22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 469] (XIV) (In the formula, L-Ar is [Chemical 470] , [Chemical 471] or [Chemical 472] is; Ar is [Chemical 473] , [Chemical 474] , [Chemical 475] , [Chemical 476] or [Chemical 477] with the proviso that L-Ar is [Chemical 478] when Ar is [Chemical 479] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 480] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 481] , [Chemical 482] or [Chemical 483] is; Ar is [Chemical 484] , [Chemical 485] , [Chemical 486] , [Chemical 487] or [Chemical 488] with the proviso that L-Ar is [Chemical 489] when Ar is [Chemical 490] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 491] (XVI) (In the formula, L-Ar is [Chemical 492] , [Chemical 493] or [Chemical 494] is; Ar is [Chemical 495] , [Chemical 496] , [Chemical 497] , [Chemical 498] or [Chemical 499] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 500] (XVII) (In the formula, L-Ar is [Chemical 501] , [Chemical 502] or [Chemical 503] is; Ar is [Chemical 504] , [Chemical 505] , [Chemical 506] , [Chemical 507] or [Chemical 508] with the proviso that L-Ar is [Chemical 509] when Ar is [Chemical 510] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 511] (XVIII) (In the formula, L-Ar is [Chemical 512] , [Chemical 513] or [Chemical 514] is; Ar is [Chemical 515] , [Chemical 516] , [Chemical 517] , [Chemical 518] or [Chemical 519] with the proviso that L-Ar is [Chemical 520] when Ar is [Chemical 521] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 522] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 523] , [Chemical 524] , [Chemical 525] , [Chemical 526] or [Chemical 527] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 528] (XX) (In the formula, L-Ar is [Chemical 529] , [Chemical 530] or [Chemical 531] is; Ar is [Chemical 532] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 533] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0109] In various aspects, the present disclosure provides a method of treating liver cancer in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 534] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 535] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 536] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 537] (XII) (In the formula, L-Ar is [Chemical 538] , [Chemical 539] or [Chemical 540] is; Ar is [Chemical 541] , [Chemical 542] , [Chemical 543] , [Chemical 544] or [Chemical 545] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 546] (XIII) (In the formula, L-Ar is [Chemical 547] , [Chemical 548] or [Chemical 549] is; Ar is [Chemical 550] , [Chemical 551] , [Chemical 552] , [Chemical 553] or [Chemical 554] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 555] (XIV) (In the formula, L-Ar is [Chemical 556] , [Chemical 557] or [Chemical 558] is; Ar is [Chemical 559] , [Chemical 560] , [Chemical 561] , [Chemical 562] or [Chemical 563] with the proviso that L-Ar is [Chemical 564] when Ar is [Chemical 565] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 566] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 567] , [Chemical 568] or [Chemical 569] is; Ar is [Chemical 570] , [Chemical 571] , [Chemical 572] , [Chemical 573] or [Chemical 574] with the proviso that L-Ar is [Chemical 575] when Ar is [Chemical 576] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 577] (XVI) (In the formula, L-Ar is [Chemical 578] , [Chemical 579] or [Chemical 580] is; Ar is [Chemical 581] , [Chemical 582] , [Chemical 583] , [Chemical 584] or [Chemical 585] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 586] (XVII) (In the formula, L-Ar is [Chemical 587] , [Chemical 588] or [Chemical 589] is; Ar is [Chemical 590] , [Chemical 591] , [Chemical 592] , [Chemical 593] or [Chemical 594] with the proviso that L-Ar is [Chemical 595] when Ar is [Chemical 596] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 597] (XVIII) (In the formula, L-Ar is [Chemical 598] , [Chemical 599] or [Chemical 600] is; Ar is [Chemical 601] , [Chemical 602] , [Chemical 603] , [Chemical 604] or [Chemical 605] with the proviso that L-Ar is [Chemical 606] when Ar is [Chemical 607] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 608] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [C609] , [Chemical 610] , [Chemical 611] , [C612] or [C613] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 614] (XX) (In the formula, L-Ar is [Chemical 615] , [Chemical 616] or [Chemical 617] is; Ar is [Chemical 618] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 619] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0110] In various aspects, the present disclosure provides a method of treating a disease or condition in which interleukin-1 beta (IL1β) levels are elevated in a subject in need thereof, comprising: to the (a) Formula (IX) [Chemical 620] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 621] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [C622] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 623] (XII) (In the formula, L-Ar is [Chemical 624] , [Chemical 625] or [Chemical 626] is; Ar is [Chemical 627] , [Chemical 628] , [Chemical 629] , [C630] or [C631] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [C632] (XIII) (In the formula, L-Ar is [C633] , [Chemical 634] or [Chemical 635] is; Ar is [Chemical 636] , [Chemical 637] , [Chemical 638] , [Chemical 639] or [Chemical 640] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [C641] (XIV) (In the formula, L-Ar is [C642] , [C643] or [C644] is; Ar is [C645] , [Chemical 646] , [Chemical 647] , [Chemical 648] or [C649] with the proviso that L-Ar is [Chemical 650] when Ar is [Chemical 651] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 652] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50-or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [C653] , [Chemical 654] or [Chemical 655] is; Ar is [Chemical 656] , [C657] , [C658] , [Chemical 659] or [Chemical 660] with the proviso that L-Ar is [Chemical 661] when Ar is [Chemical 662] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [C663] (XVI) (In the formula, L-Ar is [Chemical 664] , [Chemical 665] or [Chemical 666] is; Ar is [Chemical 667] , [C668] , [Chemical 669] , [Chemical 670] or [Chemical 671] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 672] (XVII) (In the formula, L-Ar is [Chemical 673] , [Chemical 674] or [Chemical 675] is; Ar is [Chemical 676] , [Chemical 677] , [Chemical 678] , [Chemical 679] or [Chemical 680] with the proviso that L-Ar is [Chemical 681] when Ar is [Chemical 682] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [C683] (XVIII) (In the formula, L-Ar is [C684] , [Chemical 685] or [C686] is; Ar is [C687] , [Chemical 688] , [Chemical 689] , [Chemical 690] or [C691] with the proviso that L-Ar is [Chemical 692] when Ar is [Chemical 693] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [C694] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 695] , [C696] , [C697] , [C698] or [C699] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 700] (XX) (In the formula, L-Ar is [Chemical 701] , [Chemical 702] or [Chemical 703] is; Ar is [Chemical 704] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 705] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0111] In various aspects, the present disclosure provides helper T cells (T h ) A method of treating an elevated level of a disease or condition in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 706] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 707] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t-(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 708] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 709] (XII) (In the formula, L-Ar is [Chemical 710] , [Chemical 711] or [Chemical 712] is; Ar is [Chemical 713] , [Chemical 714] , [Chemical 715] , [Chemical 716] or [Chemical 717] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 718] (XIII) (In the formula, L-Ar is [Chemical 719] , [Chemical 720] or [Chemical 721] is; Ar is [Chemical 722] , [Chemical 723] , [Chemical 724] , [Chemical 725] or [Chemical 726] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 727] (XIV) (In the formula, L-Ar is [Chemical 728] , [Chemical 729] or [Chemical 730] is; Ar is [Chemical 731] , [Chemical 732] , [Chemical 733] , [Chemical 734] or [Chemical 735] with the proviso that L-Ar is [Chemical 736] when Ar is [Chemical 737] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 738] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 739] , [Chemical 740] or [Chemical 741] is; Ar is [Chemical 742] , [Chemical 743] , [Chemical 744] , [Chemical 745] or [Chemical 746] with the proviso that L-Ar is [Chemical 747] when Ar is [Chemical 748] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 749] (XVI) (In the formula, L-Ar is [Chemical 750] , [Chemical 751] or [Chemical 752] is; Ar is [Chemical 753] , [Chemical 754] , [Chemical 755] , [Chemical 756] or [Chemical 757] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 758] (XVII) (In the formula, L-Ar is [Chemical 759] , [Chemical 760] or [Chemical 761] is; Ar is [Chemical 762] , [Chemical 763] , [Chemical 764] , [Chemical 765] or [Chemical 766] with the proviso that L-Ar is [Chemical 767] when Ar is [Chemical 768] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 769] (XVIII) (In the formula, L-Ar is [Chemical 770] , [Chemical 771] or [Chemical 772] is; Ar is [Chemical 773] , [Chemical 774] , [Chemical 775] , [Chemical 776] or [Chemical 777] with the proviso that L-Ar is [Chemical 778] when Ar is [Chemical 779] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 780] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 781] , [Chemical 782] , [Chemical 783] , [Chemical 784] or [Chemical 785] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 786] (XX) (In the formula, L-Ar is [Chemical 787] , [Chemical 788] or [Chemical 789] is; Ar is [Chemical 790] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 791] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0112] In various aspects, the present disclosure provides regulatory T cells (T reg ) is reduced or inhibited in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 792] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 793] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 794] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 795] (XII) (In the formula, L-Ar is [Chemical 796] , [Chemical 797] or [Chemical 798] is; Ar is [Chemical 799] , [Chemical 800] , [Chemical 801] , [Chemical 802] or [Chemical 803] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 804] (XIII) (In the formula, L-Ar is [Chemical 805] , [Chemical 806] or [Chemical 807] is; Ar is [Chemical 808] , [Chemical 809] , [Chemical 810] , [Chemical 811] or [Chemical 812] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 813] (XIV) (In the formula, L-Ar is [Chemical 814] , [Chemical 815] or [Chemical 816] is; Ar is [Chemical 817] , [Chemical 818] , [Chemical 819] , [Chemical 820] or [Chemical 821] with the proviso that L-Ar is [Chemical 822] when Ar is [Chemical 823] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 824] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 825] , [Chemical 826] or [Chemical 827] is; Ar is [Chemical 828] , [Chemical 829] , [Chemical 830] , [Chemical 831] or [Chemical 832] with the proviso that L-Ar is [Chemical 833] when Ar is [Chemical 834] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 835] (XVI) (In the formula, L-Ar is [Chemical 836] , [Chemical 837] or [Chemical 838] is; Ar is [Chemical 839] , [Chemical 840] , [Chemical 841] , [Chemical 842] or [Chemical 843] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 844] (XVII) (In the formula, L-Ar is [Chemical 845] , [Chemical 846] or [Chemical 847] is; Ar is [Chemical 848] , [Chemical 849] , [Chemical 850] , [Chemical 851] or [Chemical 852] with the proviso that L-Ar is [Chemical 853] when Ar is [Chemical 854] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 855] (XVIII) (In the formula, L-Ar is [Chemical 856] , [Chemical 857] or [Chemical 858] is; Ar is [Chemical 859] , [Chemical 860] , [Chemical 861] , [Chemical 862] or [Chemical 863] with the proviso that L-Ar is [Chemical 864] when Ar is [Chemical 865] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 866] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 867] , [Chemical 868] , [Chemical 869] , [Chemical 870] or [Chemical 871] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 872] (XX) (In the formula, L-Ar is [Chemical 873] , [Chemical 874] or [Chemical 875] is; Ar is [Chemical 876] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 877] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0113] In various aspects, the present disclosure provides a method of reversing established non-alcoholic steatohepatitis (NASH), comprising: (a) Formula (IX) [Chemical 878] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 879] (X) (In the formula, R. 1 is H, -CN, halogen, C 1~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 880] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 881] (XII) (In the formula, L-Ar is [Chemical 882] , [Chemical 883] or [Chemical 884] is; Ar is [Chemical 885] , [Chemical 886] , [Chemical 887] , [Chemical 888] or [Chemical 889] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 890] (XIII) (In the formula, L-Ar is [Chemical 891] , [Chemical 892] or [Chemical 893] is; Ar is [Chemical 894] , [Chemical 895] , [Chemical 896] , [Chemical 897] or [Chemical 898] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 899] (XIV) (In the formula, L-Ar is [Chemical 900] , [Chemical 901] or [Chemical 902] is; Ar is [Chemical 903] , [Chemical 904] , [Chemical 905] , [Chemical 906] or [Chemical 907] with the proviso that L-Ar is [Chemical 908] when Ar is [Chemical 909] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 910] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 911] , [Chemical 912] or [Chemical 913] is; Ar is [Chemical 914] , [Chemical 915] , [Chemical 916] , [Chemical 917] or [Chemical 918] with the proviso that L-Ar is [Chemical 919] when Ar is [Chemical 920] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 921] (XVI) (In the formula, L-Ar is [Chemical 922] , [Chemical 923] or [Chemical 924] is; Ar is [Chemical 925] , [Chemical 926] , [Chemical 927] , [Chemical 928] or [Chemical 929] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 930] (XVII) (In the formula, L-Ar is [Chemical 931] , [Chemical 932] or [Chemical 933] is; Ar is [Chemical 934] , [Chemical 935] , [Chemical 936] , [Chemical 937] or [Chemical 938] with the proviso that L-Ar is [Chemical 939] when Ar is [Chemical 940] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 941] (XVIII) (In the formula, L-Ar is [Chemical 942] , [Chemical 943] or [Chemical 944] is; Ar is [Chemical 945] , [Chemical 946] , [Chemical 947] , [Chemical 948] or [Chemical 949] with the proviso that L-Ar is [Chemical 950] when Ar is [Chemical 951] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 952] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 953] , [Chemical 954] , [Chemical 955] , [Chemical 956] or [Chemical 957] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 958] (XX) (In the formula, L-Ar is [Chemical 959] , [Chemical 960] or [Chemical 961] is; Ar is [Chemical 962] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 963] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0114] In various aspects, the present disclosure provides a method of reducing fibrosis gene expression comprising, in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 964] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 965] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 966] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 967] (XII) (In the formula, L-Ar is [Chemical 968] , [Chemical 969] or [Chemical 970] is; Ar is [Chemical 971] , [Chemical 972] , [Chemical 973] , [Chemical 974] or [Chemical 975] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 976] (XIII) (In the formula, L-Ar is [Chemical 977] , [Chemical 978] or [Chemical 979] is; Ar is [Chemical 980] , [Chemical 981] , [Chemical 982] , [Chemical 983] or [Chemical 984] is; Het is 5-6 membered heteroaryl; R. 1is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 985] (XIV) (In the formula, L-Ar is [Chemical 986] , [Chemical 987] or [Chemical 988] is; Ar is [Chemical 989] , [Chemical 990] , [Chemical 991] , [Chemical 992] or [Chemical 993] with the proviso that L-Ar is [Chemical 994] when Ar is [Chemical 995] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 996] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 997] , [Chemical 998] or [Chemical 999] is; Ar is [Chemical 1000] , [Chemical 1001] , [Chemical 1002] , [Chemical 1003] or [Chemical 1004] with the proviso that L-Ar is [Chemical 1005] when Ar is [Chemical 1006] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 1007] (XVI) (In the formula, L-Ar is [Chemical 1008] , [Chemical 1009] or [Chemical 1010] is; Ar is [Chemical 1011] , [Chemical 1012] , [Chemical 1013] , [Chemical 1014] or [Chemical 1015] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 1016] (XVII) (In the formula, L-Ar is [Chemical 1017] , [Chemical 1018] or [Chemical 1019] is; Ar is [Chemical 1020] , [Chemical 1021] , [Chemical 1022] , [Chemical 1023] or [Chemical 1024] with the proviso that L-Ar is [Chemical 1025] when Ar is [Chemical 1026] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 1027] (XVIII) (In the formula, L-Ar is [Chemical 1028] , [Chemical 1029] or [Chemical 1030] is; Ar is [Chemical 1031] , [Chemical 1032] , [Chemical 1033] , [Chemical 1034] or [Chemical 1035] with the proviso that L-Ar is [Chemical 1036] when Ar is [Chemical 1037] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 1038] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl; or 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 1039] , [Chemical 1040] , [Chemical 1041] , [Chemical 1042] or [Chemical 1043] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 1044] (XX) (In the formula, L-Ar is [Chemical 1045] , [Chemical 1046] or [Chemical 1047] is; Ar is [Chemical 1048] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 1049] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0115] In various aspects, the present disclosure provides a method of treating dermatofibrosis, comprising: (a) Formula (IX) [Chemical 1050] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 1051] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 1052] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 1053] (XII) (In the formula, L-Ar is [Chemical 1054] , [Chemical 1055] or [Chemical 1056] is; Ar is [Chemical 1057] , [Chemical 1058] , [Chemical 1059] , [Chemical 1060] or [Chemical 1061] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 1062] (XIII) (In the formula, L-Ar is [Chemical 1063] , [Chemical 1064] or [Chemical 1065] is; Ar is [Chemical 1066] , [Chemical 1067] , [Chemical 1068] , [Chemical 1069] or [Chemical 1070] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 1071] (XIV) (In the formula, L-Ar is [Chemical 1072] , [Chemical 1073] or [Chemical 1074] is; Ar is [Chemical 1075] , [Chemical 1076] , [Chemical 1077] , [Chemical 1078] or [Chemical 1079] with the proviso that L-Ar is [Chemical 1080] when Ar is [Chemical 1081] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 1082] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 1083] , [Chemical 1084] or [Chemical 1085] is; Ar is [Chemical 1086] , [Chemical 1087] , [Chemical 1088] , [Chemical 1089] or [Chemical 1090] with the proviso that L-Ar is [Chemical 1091] when Ar is [Chemical 1092] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 1093] (XVI) (In the formula, L-Ar is [Chemical 1094] , [Chemical 1095] or [Chemical 1096] is; Ar is [Chemical 1097] , [Chemical 1098] , [Chemical 1099] , [Chemical 1100] or [Chemical 1101] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R.22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 1102] (XVII) (In the formula, L-Ar is [Chemical 1103] , [Chemical 1104] or [Chemical 1105] is; Ar is [Chemical 1106] , [Chemical 1107] , [Chemical 1108] , [Chemical 1109] or [Chemical 1110] with the proviso that L-Ar is [Chemical 1111] when Ar is [Chemical 1112] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 1113] (XVIII) (In the formula, L-Ar is [Chemical 1114] , [Chemical 1115] or [Chemical 1116] is; Ar is [Chemical 1117] , [Chemical 1118] , [Chemical 1119] , [Chemical 1120] or [Chemical 1121] with the proviso that L-Ar is [Chemical 1122] when Ar is [Chemical 1123] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 1124] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 1125] , [Chemical 1126] , [Chemical 1127] , [Chemical 1128] or [Chemical 1129] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 1130] (XX) (In the formula, L-Ar is [Chemical 1131] , [Chemical 1132] or [Chemical 1133] is; Ar is [Chemical 1134] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 1135] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof, comprising administering a fatty acid synthase inhibitor.

[0116] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating non-alcoholic steatohepatitis (NASH) or a symptom of NASH. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used to treat non-alcoholic steatohepatitis (NASH) or a symptom of NASH.

[0117] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating non-alcoholic fatty liver disease (NAFLD). In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used to treat non-alcoholic fatty liver disease (NAFLD).

[0118] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating metabolic syndrome. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat metabolic syndrome.

[0119] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating liver cirrhosis. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat liver cirrhosis.

[0120] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating liver fibrosis. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat liver fibrosis.

[0121] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used for the manufacture of a medicament for treating liver cancer. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat liver cancer.

[0122] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating liver fibrosis. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat liver fibrosis.

[0123] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating a disease or condition in which interleukin-1 beta (IL1β) levels are elevated. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used to treat a disease or condition in which interleukin-1 beta (IL1β) levels are elevated.

[0124] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or a compound as described in Table 1, into T helper cells (T h ) can be used in the manufacture of a medicament to treat a disease or condition in which elevated levels are present. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or a compound as described in Table 1, into T helper cells (T h ) can be used to treat diseases or conditions with elevated levels.

[0125] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are regulatory T cells (T reg ) is reduced or inhibited in the manufacture of a medicament for treating a disease or condition. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are Compounds having or as described in Table 1 can be used in diseases or conditions in which regulatory T cells (Treg) are reduced or suppressed.

[0126] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating or reversing established non-alcoholic steatohepatitis (NASH). In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are Compounds having or as described in Table 1 can be used to treat or reverse non-alcoholic steatohepatitis (NASH).

[0127] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used in the manufacture of a medicament for reducing fibrosis gene expression. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to reduce fibrosis gene expression.

[0128] In various embodiments, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are A compound having or as described in Table 1 can be used in the manufacture of a medicament for treating dermal fibrosis. In a further embodiment, structures (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI) are or compounds as described in Table 1 can be used to treat dermal fibrosis. [Brief description of the drawing]

[0129]

Figure 1

Figure 2

[0130] The present disclosure addresses deficiencies in the treatment of conditions characterized by dysregulation of FASN function in subjects, such as viral infections, cancer and metabolic disorders, by providing novel heterocyclic modulators of lipid synthesis.

[0131] In certain aspects, the present disclosure provides compositions and methods for treatment of viral infections. Generally, the present compositions and methods for treatment of viral infections relate to modulation of fatty acid synthesis pathways. This fatty acid synthesis pathway is involved in viral replication into host cells. The present invention embodies methods for the treatment of viral infections, such as hepatitis C infection, yellow fever infection and human rhinovirus infection, or any virus that targets the fatty acid synthesis pathway.

[0132] In certain aspects, the disclosure provides compositions and methods for the treatment of cancer. Fatty acid synthase is involved in the conversion of malonyl-CoA to long-chain fatty acids, an early reaction in fatty acid biosynthesis. Fatty acid synthases are overexpressed in many cancer cells. Without being bound by any particular theory, inhibition of fatty acid synthase expression or fatty acid synthase activity selectively inhibits cancer cell proliferation, induces cell death of cancer cells, and induces cell death in normal cells. is assumed to have little toxicity.

[0133] Additionally, the present disclosure provides compounds and methods for modulating host cell targets targeted by viruses. Such modulation of host cell targets may involve activation or inhibition of host cell targets. Accordingly, compounds that modulate, eg, inhibit, the activity of non-viral proteins, eg, host cell proteins, eg, components of the fatty acid synthesis pathway, can be used as antiviral pharmaceuticals.

[0134] definition Chemical moieties referred to as monovalent chemical moieties (eg, alkyl, aryl, etc.) also include structurally permissible multivalent moieties, as understood by those skilled in the art. For example, an "alkyl" moiety generally refers to a monovalent radical (eg, CH 3 CH 2 -), but in appropriate circumstances the "alkyl" moiety is a divalent radical (e.g., -CH 2 CH 2 -, which is equivalent to an “alkylene” group). Similarly, in situations where a divalent moiety is required, the term "aryl" will be understood by those skilled in the art to refer to the corresponding divalent arylene group.

[0135] All atoms have their normal valences for bond formation (e.g. 4 for carbon, 3 for N, 2 for O, 2, 4 or 6 for S depending on the oxidation state of the atom). It is understood to have Occasionally, a part is e.g. (A) a Sometimes defined as B (where a is 0 or 1). In such a case, the portion is B when a is 0 and AB when a is 1.

[0136] Substituents can vary in the number of atoms or groups of the same type (e.g., alkyl groups are C 1 , C 2 , C 3 etc.), the number of repeating atoms or groups should be a range (e.g. C 1 ~C 6 alkyl) and this range includes each and every number within this range and any and all subranges. For example, C 1 ~C 3 Alkyl is C 1 , C 2 , C 3 , C 1〜2 , C 1〜3 and C 2〜3 Contains alkyl.

[0137] "Alkanoyl" refers to a carbonyl group substituted with a lower alkyl group.

[0138] "Alkylamino" refers to an amino group substituted with an alkyl group.

[0139] "Alkoxy" means an O atom substituted by an alkyl group as defined herein, e.g. methoxy[-OCH 3 , C 1 alkoxy]. The term "C 1〜6 alkoxy” is C 1 Alkoxy, C 2 Alkoxy, C 3 Alkoxy, C 4 Alkoxy, C 5 Alkoxy, C 6 Alkoxy and any subranges thereof are included.

[0140] "Alkoxycarbonyl" refers to a carbonyl group having an alkoxy group as a substituent.

[0141] "Alkyl", "alkenyl" and "alkynyl" are optionally substituted groups having 1-30 carbon atoms, preferably 1-15 carbon atoms, more preferably 1-6 carbon atoms. refers to straight- and branched-chain aliphatic groups. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, isobutyl, pentyl, hexyl, vinyl, allyl, isobutenyl, ethynyl and propynyl. The term "heteroalkyl," as used herein, contemplates alkyl having one or more heteroatoms.

[0142] "Alkylene" refers to an optionally substituted divalent group that is a branched or unbranched hydrocarbon fragment containing the specified number of carbon atoms and having two points of attachment. An example is propylene [-CH2 CH 2 CH 2 -, C 3 alkylene].

[0143] "Amino" means -NH 2 refers to the group of

[0144] "Aryl" refers to an optionally substituted aromatic group having at least one ring with a conjugated pi electron system, including carbocyclic aryl and biaryl groups, all of which are optionally substituted get). Phenyl and naphthyl groups are preferred carbocyclic aryl groups.

[0145] "Aralkyl" or "arylalkyl" refer to alkyl-substituted aryl groups. Examples of aralkyl groups include butylphenyl, propylphenyl, ethylphenyl, methylphenyl, 3,5-dimethylphenyl, tert-butylphenyl.

[0146] "Carbamoyl" as used herein has the structure [Chemical 1136] (In the formula, R N is hydrogen, -OH, C 1 ~C 12 Alkyl, C 1 ~C 12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, sulfonyl, sulfonate and sulfonamide) groups are contemplated. .

[0147] "Carbonyl" means the structure [Chemical 1137] refers to the group of

[0148] "Cycloalkyl" means an optionally substituted ring composed entirely of carbon, which may be saturated or unsaturated, and may be monocyclic, bicyclic or tricyclic refers to a ring that may be a formula. Examples of cycloalkyl groups include 5 carbons (C 5 ), an unsaturated cycloalkyl group, a cyclopentenyl group (C 5 H. 7 -).

[0149] "Heterocycle" refers to an optionally substituted 5- to 7-membered cycloalkyl ring system containing 1, 2 or 3 heteroatoms and optionally containing 1 double bond , the heteroatoms may be the same or different and may be selected from N, O or S.

[0150] "Halogen" refers to an atomic group of chlorine, bromine, fluorine or iodine. The term "halogen" also contemplates the term "halo" or "halide".

[0151] "Heteroatom" refers to non-carbon atoms, with boron, nitrogen, oxygen, sulfur and phosphorus being preferred heteroatoms, with nitrogen, oxygen and sulfur being particularly preferred heteroatoms in the compounds of this disclosure.

[0152] "Heteroaryl" refers to optionally substituted aryl groups having from 1 to 9 carbon atoms, the remainder of the atoms being heteroatoms, as described in "Handbook of Chemistry and Physics," 49th edition, 1968, R.C. West, editor; The Chemical Rubber Co., Cleveland, Ohio. See especially Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems. Suitable heteroaryls include thienyl, pyrrolyl, furyl, pyridyl, pyrimidyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, pyranyl, tetrazolyl, pyrrolyl, pyrrolinyl, pyridazinyl, triazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl, oxadiazolyl, benzoxazolyl, benzoxadiazolyl, thiadiazolyl, benzothiazolyl, benzothiadiazolyl and the like.

[0153] An "optionally substituted" moiety may be substituted with 1 to 4, preferably 1 to 3, more preferably 1 or 2, non-hydrogen substituents. Unless otherwise specified, when a substituent is on a carbon it means -OH, -CN, -NO 2 , Halogen, C 1 ~C 12 Alkyl, C 1 ~C 12 selected from the group consisting of heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate, sulfonamide and amino, none of which are further substituted . Unless otherwise specified, when a substituent is on a nitrogen it is a C 1 ~C 12 Alkyl, C 1 ~C 12 selected from the group consisting of heteroalkyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, sulfonyl, sulfonate and sulfonamide, none of which are further substituted.

[0154] As used herein, the term "sulfonand" refers to the structure [Chemical 1138] (In the formula, R N is hydrogen, -OH, C 1 ~C 12 Alkyl, C 1 ~C 12 heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycle, aryl, heteroaryl, aralkyl, alkoxy, alkoxycarbonyl, alkanoyl, carbamoyl, substituted sulfonyl, sulfonate and sulfonamide). ing.

[0155] The term "sulfonate" as used herein refers to the structure [Chemical 1139] (In the formula, R s is hydrogen, C 1 ~C 10 Alkyl, C 2 ~C 10 alkenyl, C 2 ~C 10 alkynyl, C 1 ~C 10 alkanoyl, or C 1 ~C 10 alkoxycarbonyl) are contemplated.

[0156] "Sulfonyl" when used herein alone or as part of another group means SO 2 point to the base. SO 2 Parts have been substituted where appropriate.

[0157] The compounds of this disclosure may exist as stereoisomers wherein asymmetric or chiral centers are present. Stereoisomers are designated (R) or (S) depending on the configuration of substituents around the chiral carbon atom. As used herein, the terms (R) and (S) are defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., (1976), 45:13-30, which is incorporated herein by reference. The configuration is as defined in This disclosure contemplates various stereoisomers and mixtures thereof and are expressly included within the scope of this disclosure. Stereoisomers include enantiomers, diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of the compounds of the present disclosure can be prepared synthetically from commercially available starting materials containing asymmetric or chiral centers, or by preparation of racemic mixtures followed by resolution well known to those skilled in the art. can be prepared. These resolution methods consist of (1) coupling of the enantiomeric mixture to a chiral auxiliary, separation of the resulting diastereomeric mixture by recrystallization or chromatography, and liberation of the optically pure product from the auxiliary. or (2) by direct separation of optical enantiomeric mixtures on a chiral chromatography column.

[0158] Also, moieties disclosed herein that exist in multiple tautomeric forms include all such forms that are encompassed by a given tautomeric structure.

[0159] Individual atoms in the compounds of this disclosure may be any isotope of that element. For example, hydrogen may be in the form of deuterium.

[0160] "Pharmaceutically acceptable" means approved or may be approved by a federal or state regulatory agency for use in animals, and more particularly for use in humans; Means that it is listed in another generally recognized pharmacopoeia. It can be a material that is not biological or otherwise undesirable. That is, the material can be administered to an individual without producing any undesired biological effects or adversely interacting with any component of the composition containing the material.

[0161] The term "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of its parent compound. Such salts include, for example, acid addition salts and base addition salts.

[0162] "Acid addition salts" according to the present disclosure are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid; or organic acids such as acetic acid, propionic acid, hexanoic acid, cyclo Pentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandel acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene -1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, glucone Formed with acids, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like.

[0163] A "base addition salt" according to the present disclosure is when an acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal, alkaline earth or aluminum ion, or coordinated to an organic base. formed when Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like. References to pharmaceutically acceptable salts should be understood to include solvent addition forms or crystalline forms thereof, especially solvates or polymorphs. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and are often formed during the process of crystallization. Hydrates are formed when the solvent is water and alcoholates are formed when the solvent is alcohol. Polymorphism includes different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. Various factors such as recrystallization solvent, crystallization rate and storage temperature can cause the single crystal form to predominate.

[0164] The term "treating" includes the use of the present invention to prevent or slow, alleviate, or arrest or inhibit the development of symptoms or conditions associated with a fatty acid synthase-related disorder, e.g., cancer-associated tumor growth. Including administering a compound or agent to a subject. A skilled health care practitioner uses standard methods for determining whether a patient is suffering from a disease associated with fatty acid synthase activity, e.g., examining the patient and determining whether the patient is associated with fatty acid synthase activity. or assaying for fatty acid synthase levels in the plasma or tissue of an individual suspected of having a fatty acid synthase-related disease, Know how to use the method by comparing fatty acid synthase levels in the plasma or tissue of an individual suspected of having the relevant disease with those in the plasma or tissue of a healthy individual. Increased securin levels indicate disease. Accordingly, the invention provides, inter alia, methods of administering compounds of the invention to a subject and methods of determining fatty acid synthase activity in a subject. Fatty acid synthase activity in a subject can be determined before and / or after administration of the compound.

[0165] A "therapeutically effective amount" or "pharmaceutically effective amount" means an amount that, when administered to a subject, produces its administered effects. For example, a "therapeutically effective amount" is an amount sufficient to inhibit fatty acid synthase activity when administered to a subject to inhibit fatty acid synthase activity. A "therapeutically effective amount" is an amount sufficient to effect treatment for a disease when administered to a subject to treat the disease.

[0166] Unless otherwise stated, the terms "subject" or "patient" are used interchangeably and include mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, rats and mice as well as other animals. Also refers to animals. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the compounds of the present invention can be administered. In an exemplary embodiment of the invention, an acceptable screening method is used to identify risk factors associated with the disease or condition of interest or suspected in order to identify eligible patients for treatment by the methods of the invention. determine or determine the status of an existing disease or condition in a subject. These screening methods include, for example, conventional work-ups to determine risk factors associated with the disease or condition of interest or suspected. These and other routine methods allow clinicians to select patients in need of treatment using the methods and formulations of the present invention.

[0167] FASN pathway modulator One aspect of the present disclosure includes a method of inhibiting viral infection or treating cancer by contacting a cell with an agent that modulates the fatty acid synthesis pathway. This method of inhibiting viral infection or treating cancer can be performed in vitro by contacting a virus-infected / cancerous cell with an agent that modulates the fatty acid synthesis pathway, or infected with a virus. This can be done in vivo by administering an agent that modulates the fatty acid synthesis pathway to a subject / subject with cancer. In one embodiment, the agent can be an inhibitor of the fatty acid synthetic pathway.

[0168] Examples of inhibitors of fatty acid synthetic pathways that can be used in the methods and compositions of the present disclosure are described below.

[0169] Compounds of Structure (I) In various aspects, the present disclosure provides compounds of structure (I): [Chemical 1140] (I) (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; A is CH or N; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl; or 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R.14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino; R. 17 and R 18 are each independently hydrogen or alkyl, or optionally linked together to form a bond; n is 1 or 2; m is 0 or 1) or a pharmaceutically acceptable salt thereof.

[0170] In certain embodiments of Structure (I), R 3 is F.

[0171] In certain embodiments of structure (I), A is CH.

[0172] In certain embodiments of structure (I), A is N.

[0173] In certain embodiments of structure (I), X, Y and Z are NR'.

[0174] In certain embodiments of Structure (I), R 4 is heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1 ~ 6 Alkyl, C 1 ~ 6 is alkoxy, or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl.

[0175] In certain embodiments of Structure (I), R 5 is hydrogen and R 6 is aryl or heteroaryl.

[0176] In certain embodiments, the compound of structure (I) has the structure (I-A) or (I-B): [Chemical 1141] (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13 )(R 14 ), -(CH 2 ) q C(=O)N(R 13 )(R 14 ), CF 3 , -OCF 3 , or -S(=O) 2 R. 20 is; q is 0, 1, 2, 3 or 4; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently hydrogen, C 1〜6 Alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, hydroxyalkyl, alkylamino, -N(R 15 R. 16 ), or -S(=O) 2 R. 20 is; R. 15 and R 16 are each independently hydrogen, C 1〜6 is alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino; R. 17 and R 18 are each independently hydrogen or alkyl, or optionally linked together to form a bond) or have one of the structures of a pharmaceutically acceptable salt thereof.

[0177] In certain embodiments, the compound of structure (I) has the structure (I-C) or (I-D): [Chemical 1142] (In the formula, X, Y and Z are each independently CR or NR', where R is hydrogen or C 1〜6 alkyl, R’ is hydrogen, C 1〜6 alkyl, or absent; R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl, or R 2 and R3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 and R 10 are each independently H, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(R 15 R. 16 ) and; R. 15 and R 16 are each independently H, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino) or a pharmaceutically acceptable salt structure thereof.

[0178] In certain embodiments, the compound of structure (I) has the structure (I-E), (I-F), (I-G), (I-H): [Chemical 1143] (In the formula, R. 2 is hydrogen, halo, C 1〜6 Alkoxy, C 1〜6 is alkyl, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 3 is hydrogen, hydroxyl, halo, C 1〜6 Alkyl, C 1〜6 is alkoxy, or R 2 and R 3 together with the atoms to which they are attached form a 5-membered heterocyclyl; R. 4 is hydrogen, heteroaryl, heterocyclyl, -C(=O)N(R 5 R. 6 ), -N(R 7 )C(=O)R 8 , -N(R 9 R. 10 ), C 1〜6 Alkyl, C 1〜6 Alkoxy, -S(=O) 2 R. 20 or R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl; R. 20 is hydrogen or C 1〜6 Alkyl, C 1〜6 alkoxy, or -N(R 13 )(R 14 ) and; R. 11 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 and R 4 and R 11 are joined together with the atoms to which they are attached to form a heteroaryl, or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 12 is hydrogen, halo, cyano, C 1〜6 Alkyl, C 1〜6 Alkoxy, -N(R 13 R. 14 ), CF 3 , -OCF 3 , -S(=O) 2 R. 20 or R 11 and R 12 are joined together with the atoms to which they are attached to form a heteroaryl; R. 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 13 and R 14 are each independently H, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkylamino, or -N(R 15 R. 16 ) and; R. 15 and R 16 are each independently H, C 1〜6 alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl or alkylamino) or a pharmaceutically acceptable salt structure thereof.

[0179] In certain embodiments, the compound of structure (I) has the structure (I-I), (I-J) or (I-K): [Chemical 1144] (In the formula, X and Y are each independently CR or NR', where R is H or C 1〜6 is alkyl and R' is H, C 1〜6 alkyl, or absent; R. 1 is hydrogen, cyano, halo, C 1〜6 Alkyl, C 1〜6 Alkoxy, -C(=O)N(R 13...

Claims

1. A method of treating fatty liver disease in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 2065] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2066] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2067] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2068] (XII) (In the formula, L-Ar is [Chemical 2069] 、 [Chemical 2070] or [Chemical 2071] is; Ar is [Chemical 2072] 、 [Chemical 2073] 、 [Chemical 2074] 、 [Chemical 2075] or [Chemical 2076] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2077] (XIII) (In the formula, L-Ar is [Chemical 2078] 、 [Chemical 2079] or [Chemical 2080] is; Ar is [Chemical 2081] 、 [Chemical 2082] 、 [Chemical 2083] 、 [Chemical 2084] or [Chemical 2085] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2086] (XIV) (In the formula, L-Ar is [Chemical 2087] 、 [Chemical 2088] or [Chemical 2089] is; Ar is [Chemical 2090] 、 [Chemical 2091] 、 [Chemical 2092] 、 [Chemical 2093] or [Chemical 2094] with the proviso that L-Ar is [Chemical 2095] When , Ar is [Chemical 2096] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2097] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2098] 、 [Chemical 2099] or [Chemical 2100] is; Ar is [Chemical 2101] 、 [Chemical 2102] 、 [Chemical 2103] 、 [Chemical 2104] or [Chemical 2105] with the proviso that L-Ar is [Chemical 2106] When , Ar is [Chemical 2107] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2108] (XVI) (In the formula, L-Ar is [Chemical 2109] 、 [Chemical 2110] or [Chemical 2111] is; Ar is [Chemical 2112] 、 [Chemical 2113] 、 [Chemical 2114] 、 [Chemical 2115] or [Chemical 2116] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2117] (XVII) (In the formula, L-Ar is [Chemical 2118] 、 [Chemical 2119] or [Chemical 2120] is; Ar is [Chemical 2121] 、 [Chemical 2122] 、 [Chemical 2123] 、 [Chemical 2124] or [Chemical 2125] with the proviso that L-Ar is [Chemical 2126] When , Ar is [Chemical 2127] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2128] (XVIII) (In the formula, L-Ar is [Chemical 2129] 、 [Chemical 2130] or [Chemical 2131] is; Ar is [Chemical 2132] 、 [Chemical 2133] 、 [Chemical 2134] 、 [Chemical 2135] or [Chemical 2136] with the proviso that L-Ar is [Chemical 2137] when Ar is [Chemical 2138] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2139] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2140] 、 [Chemical 2141] 、 [Chemical 2142] 、 [Chemical 2143] or [Chemical 2144] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2145] (XX) (In the formula, L-Ar is [Chemical 2146] 、 [Chemical 2147] or [Chemical 2148] is; Ar is [Chemical 2149] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2150] (XI) During the ceremony, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

2. 2. The method of claim 1, wherein said fatty liver disease is selected from non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

3. 3. The method of claim 1 or 2, wherein the fatty liver disease is non-alcoholic steatohepatitis (NASH).

4. 4. The method of any one of claims 1-3, wherein the fatty acid synthase inhibitor has the formula (IX), (X), (XII), (XIV), (XV) or (XX).

5. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (IX).

6. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (X).

7. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (XII).

8. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (XIV).

9. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (XV).

10. 5. The method of any one of claims 1-4, wherein the fatty acid synthase inhibitor has the formula (XX).

11. The fatty acid synthase inhibitor is [Chemical 2151] 5. The method of any one of claims 1-4, selected from

12. The fatty acid synthase inhibitor is [Chemical 2152] 5. The method of any one of claims 1-4, selected from

13. 1. A method of treating non-alcoholic steatohepatitis (NASH), comprising: (a) Formula (IX) [Chemical 2153] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2154] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2155] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2156] (XII) (In the formula, L-Ar is [Chemical 2157] 、 [Chemical 2158] or [Chemical 2159] is; Ar is [Chemical 2160] 、 [Chemical 2161] 、 [Chemical 2162] 、 [Chemical 2163] or [Chemical 2164] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2165] (XIII) (In the formula, L-Ar is [Chemical 2166] 、 [Chemical 2167] or [Chemical 2168] is; Ar is [Chemical 2169] 、 [Chemical 2170] 、 [Chemical 2171] 、 [Chemical 2172] or [Chemical 2173] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2174] (XIV) (In the formula, L-Ar is [Chemical 2175] 、 [Chemical 2176] or [Chemical 2177] is; Ar is [Chemical 2178] 、 [Chemical 2179] 、 [Chemical 2180] 、 [Chemical 2181] or [Chemical 2182] with the proviso that L-Ar is [Chemical 2183] When , Ar is [Chemical 2184] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2185] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2186] 、 [Chemical 2187] or [Chemical 2188] is; Ar is [Chemical 2189] 、 [Chemical 2190] 、 [Chemical 2191] 、 [Chemical 2192] or [Chemical 2193] with the proviso that L-Ar is [Chemical 2194] when Ar is [Chemical 2195] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2196] (XVI) (In the formula, L-Ar is [Chemical 2197] 、 [Chemical 2198] or [Chemical 2199] is; Ar is [Chemical 2200] 、 [Chemical 2201] 、 [Chemical 2202] 、 [Chemical 2203] or [Chemical 2204] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2205] (XVII) (In the formula, L-Ar is [Chemical 2206] 、 [Chemical 2207] or [Chemical 2208] is; Ar is [Chemical 2209] 、 [Chemical 2210] 、 [Chemical 2211] 、 [Chemical 2212] or [Chemical 2213] with the proviso that L-Ar is [Chemical 2214] when Ar is [Chemical 2215] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2216] (XVIII) (In the formula, L-Ar is [Chemical 2217] 、 [Chemical 2218] or [Chemical 2219] is; Ar is [Chemical 2220] 、 [Chemical 2221] 、 [Chemical 2222] 、 [Chemical 2223] or [Chemical 2224] with the proviso that L-Ar is [Chemical 2225] When , Ar is [Chemical 2226] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2227] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2228] 、 [Chemical 2229] 、 [Chemical 2230] 、 [Chemical 2231] or [Chemical 2232] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2233] (XX) (In the formula, L-Ar is [Chemical 2234] 、 [Chemical 2235] or [Chemical 2236] is; Ar is [Chemical 2237] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2238] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

14. A method of treating non-alcoholic fatty liver disease (NAFLD), comprising: (a) Formula (IX) [Chemical 2239] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2240] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2241] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2242] (XII) (In the formula, L-Ar is [Chemical 2243] 、 [Chemical 2244] or [Chemical 2245] is; Ar is [Chemical 2246] 、 [Chemical 2247] 、 [Chemical 2248] 、 [Chemical 2249] or [Chemical 2250] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2251] (XIII) (In the formula, L-Ar is [Chemical 2252] 、 [Chemical 2253] or [Chemical 2254] is; Ar is [Chemical 2255] 、 [Chemical 2256] 、 [Chemical 2257] 、 [Chemical 2258] or [Chemical 2259] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2260] (XIV) (In the formula, L-Ar is [Chemical 2261] 、 [Chemical 2262] or [Chemical 2263] is; Ar is [Chemical 2264] 、 [Chemical 2265] 、 [Chemical 2266] 、 [Chemical 2267] or [Chemical 2268] with the proviso that L-Ar is [Chemical 2269] when Ar is [Chemical 2270] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2271] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2272] 、 [Chemical 2273] or [Chemical 2274] is; Ar is [Chemical 2275] 、 [Chemical 2276] 、 [Chemical 2277] 、 [Chemical 2278] or [Chemical 2279] with the proviso that L-Ar is [Chemical 2280] when Ar is [Chemical 2281] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2282] (XVI) (In the formula, L-Ar is [Chemical 2283] 、 [Chemical 2284] or [Chemical 2285] is; Ar is [Chemical 2286] 、 [Chemical 2287] 、 [Chemical 2288] 、 [Chemical 2289] or [Chemical 2290] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2291] (XVII) (In the formula, L-Ar is [Chemical 2292] 、 [Chemical 2293] or [Chemical 2294] is; Ar is [Chemical 2295] 、 [Chemical 2296] 、 [Chemical 2297] 、 [Chemical 2298] or [Chemical 2299] with the proviso that L-Ar is [Chemical 2300] When , Ar is [Chemical 2301] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2302] (XVIII) (In the formula, L-Ar is [Chemical 2303] 、 [Chemical 2304] or [Chemical 2305] is; Ar is [Chemical 2306] 、 [Chemical 2307] 、 [Chemical 2308] 、 [Chemical 2309] or [Chemical 2310] with the proviso that L-Ar is [Chemical 2311] when Ar is [Chemical 2312] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2313] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2314] 、 [Chemical 2315] 、 [Chemical 2316] 、 [Chemical 2317] or [Chemical 2318] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2319] (XX) (In the formula, L-Ar is [Chemical 2320] 、 [Chemical 2321] or [Chemical 2322] is; Ar is [Chemical 2323] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2324] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

15. A method of treating metabolic syndrome, comprising: (a) Formula (IX) [Chemical 2325] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2326] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2327] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2328] (XII) (In the formula, L-Ar is [Chemical 2329] 、 [Chemical 2330] or [Chemical 2331] is; Ar is [Chemical 2332] 、 [Chemical 2333] 、 [Chemical 2334] 、 [Chemical 2335] or [Chemical 2336] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2337] (XIII) (In the formula, L-Ar is [Chemical 2338] 、 [Chemical 2339] or [Chemical 2340] is; Ar is [Chemical 2341] 、 [Chemical 2342] 、 [Chemical 2343] 、 [Chemical 2344] or [Chemical 2345] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2346] (XIV) (In the formula, L-Ar is [Chemical 2347] 、 [Chemical 2348] or [Chemical 2349] is; Ar is [Chemical 2350] 、 [Chemical 2351] 、 [Chemical 2352] 、 [Chemical 2353] or [Chemical 2354] with the proviso that L-Ar is [Chemical 2355] when Ar is [Chemical 2356] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2357] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2358] 、 [Chemical 2359] or [Chemical 2360] is; Ar is [Chemical 2361] 、 [Chemical 2362] 、 [Chemical 2363] 、 [Chemical 2364] or [Chemical 2365] with the proviso that L-Ar is [Chemical 2366] when Ar is [Chemical 2367] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2368] (XVI) (In the formula, L-Ar is [Chemical 2369] 、 [Chemical 2370] or [Chemical 2371] is; Ar is [Chemical 2372] 、 [Chemical 2373] 、 [Chemical 2374] 、 [Chemical 2375] or [Chemical 2376] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2377] (XVII) (In the formula, L-Ar is [Chemical 2378] 、 [Chemical 2379] or [Chemical 2380] is; Ar is [Chemical 2381] 、 [Chemical 2382] 、 [Chemical 2383] 、 [Chemical 2384] or [Chemical 2385] with the proviso that L-Ar is [Chemical 2386] When , Ar is [Chemical 2387] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2388] (XVIII) (In the formula, L-Ar is [Chemical 2389] 、 [Chemical 2390] or [Chemical 2391] is; Ar is [Chemical 2392] 、 [Chemical 2393] 、 [Chemical 2394] 、 [Chemical 2395] or [Chemical 2396] with the proviso that L-Ar is [Chemical 2397] when Ar is [Chemical 2398] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2399] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl; or 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2400] 、 [Chemical 2401] 、 [Chemical 2402] 、 [Chemical 2403] or [Chemical 2404] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2405] (XX) (In the formula, L-Ar is [Chemical 2406] 、 [Chemical 2407] or [Chemical 2408] is; Ar is [Chemical 2409] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2410] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

16. A method of treating liver cirrhosis, comprising: (a) Formula (IX) [Chemical 2411] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2412] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2413] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2414] (XII) (In the formula, L-Ar is [Chemical 2415] 、 [Chemical 2416] or [Chemical 2417] is; Ar is [Chemical 2418] 、 [Chemical 2419] 、 [Chemical 2420] 、 [Chemical 2421] or [Chemical 2422] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2423] (XIII) (In the formula, L-Ar is [Chemical 2424] 、 [Chemical 2425] or [Chemical 2426] is; Ar is [Chemical 2427] 、 [Chemical 2428] 、 [Chemical 2429] 、 [Chemical 2430] or [Chemical 2431] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2432] (XIV) (In the formula, L-Ar is [Chemical 2433] 、 [Chemical 2434] or [Chemical 2435] is; Ar is [Chemical 2436] 、 [Chemical 2437] 、 [Chemical 2438] 、 [Chemical 2439] or [Chemical 2440] with the proviso that L-Ar is [Chemical 2441] when Ar is [Chemical 2442] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2443] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2444] 、 [Chemical 2445] or [Chemical 2446] is; Ar is [Chemical 2447] 、 [Chemical 2448] 、 [Chemical 2449] 、 [Chemical 2450] or [Chemical 2451] with the proviso that L-Ar is [Chemical 2452] When , Ar is [Chemical 2453] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2454] (XVI) (In the formula, L-Ar is [Chemical 2455] 、 [Chemical 2456] or [Chemical 2457] is; Ar is [Chemical 2458] 、 [Chemical 2459] 、 [Chemical 2460] 、 [Chemical 2461] or [Chemical 2462] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2463] (XVII) (In the formula, L-Ar is [Chemical 2464] 、 [Chemical 2465] or [Chemical 2466] is; Ar is [Chemical 2467] 、 [Chemical 2468] 、 [Chemical 2469] 、 [Chemical 2470] or [Chemical 2471] with the proviso that L-Ar is [Chemical 2472] when Ar is [Chemical 2473] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2474] (XVIII) (In the formula, L-Ar is [Chemical 2475] 、 [Chemical 2476] or [Chemical 2477] is; Ar is [Chemical 2478] 、 [Chemical 2479] 、 [Chemical 2480] 、 [Chemical 2481] or [Chemical 2482] with the proviso that L-Ar is [Chemical 2483] when Ar is [Chemical 2484] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2485] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2486] 、 [Chemical 2487] 、 [Chemical 2488] 、 [Chemical 2489] or [Chemical 2490] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2491] (XX) (In the formula, L-Ar is [Chemical 2492] 、 [Chemical 2493] or [Chemical 2494] is; Ar is [Chemical 2495] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2496] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

17. A method of treating liver fibrosis, comprising: (a) Formula (IX) [Chemical 2497] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2498] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2499] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2500] (XII) (In the formula, L-Ar is [Chemical 2501] 、 [Chemical 2502] or [Chemical 2503] is; Ar is [Chemical 2504] 、 [Chemical 2505] 、 [Chemical 2506] 、 [Chemical 2507] or [Chemical 2508] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2509] (XIII) (In the formula, L-Ar is [Chemical 2510] 、 [Chemical 2511] or [Chemical 2512] is; Ar is [Chemical 2513] 、 [Chemical 2514] 、 [Chemical 2515] 、 [Chemical 2516] or [Chemical 2517] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2518] (XIV) (In the formula, L-Ar is [Chemical 2519] 、 [Chemical 2520] or [Chemical 2521] is; Ar is [Chemical 2522] 、 [Chemical 2523] 、 [Chemical 2524] 、 [Chemical 2525] or [Chemical 2526] with the proviso that L-Ar is [Chemical 2527] When , Ar is [Chemical 2528] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2529] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2530] 、 [Chemical 2531] or [Chemical 2532] is; Ar is [Chemical 2533] 、 [Chemical 2534] 、 [Chemical 2535] 、 [Chemical 2536] or [Chemical 2537] with the proviso that L-Ar is [Chemical 2538] when Ar is [Chemical 2539] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2540] (XVI) (In the formula, L-Ar is [Chemical 2541] 、 [Chemical 2542] or [Chemical 2543] is; Ar is [Chemical 2544] 、 [Chemical 2545] 、 [Chemical 2546] 、 [Chemical 2547] or [Chemical 2548] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2549] (XVII) (In the formula, L-Ar is [Chemical 2550] 、 [Chemical 2551] or [Chemical 2552] is; Ar is [Chemical 2553] 、 [Chemical 2554] 、 [Chemical 2555] 、 [Chemical 2556] or [Chemical 2557] with the proviso that L-Ar is [Chemical 2558] When , Ar is [Chemical 2559] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2560] (XVIII) (In the formula, L-Ar is [Chemical 2561] 、 [Chemical 2562] or [Chemical 2563] is; Ar is [Chemical 2564] 、 [Chemical 2565] 、 [Chemical 2566] 、 [Chemical 2567] or [Chemical 2568] with the proviso that L-Ar is [Chemical 2569] When , Ar is [Chemical 2570] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2571] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2572] 、 [Chemical 2573] 、 [Chemical 2574] 、 [Chemical 2575] or [Chemical 2576] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2577] (XX) (In the formula, L-Ar is [Chemical 2578] 、 [Chemical 2579] or [Chemical 2580] is; Ar is [Chemical 2581] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2582] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

18. A method of treating liver cancer, comprising: (a) Formula (IX) [Chemical 2583] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2584] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2585] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2586] (XII) (In the formula, L-Ar is [Chemical 2587] 、 [Chemical 2588] or [Chemical 2589] is; Ar is [Chemical 2590] 、 [Chemical 2591] 、 [Chemical 2592] 、 [Chemical 2593] or [Chemical 2594] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2595] (XIII) (In the formula, L-Ar is [Chemical 2596] 、 [Chemical 2597] or [Chemical 2598] is; Ar is [Chemical 2599] 、 [Chemical 2600] 、 [Chemical 2601] 、 [Chemical 2602] or [Chemical 2603] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2604] (XIV) (In the formula, L-Ar is [Chemical 2605] 、 [Chemical 2606] or [Chemical 2607] is; Ar is [Chemical 2608] 、 [Chemical 2609] 、 [Chemical 2610] 、 [Chemical 2611] or [Chemical 2612] with the proviso that L-Ar is [Chemical 2613] When , Ar is [Chemical 2614] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2615] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2616] 、 [Chemical 2617] or [Chemical 2618] is; Ar is [Chemical 2619] 、 [Chemical 2620] 、 [Chemical 2621] 、 [Chemical 2622] or [Chemical 2623] with the proviso that L-Ar is [Chemical 2624] When , Ar is [Chemical 2625] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2626] (XVI) (In the formula, L-Ar is [Chemical 2627] 、 [Chemical 2628] or [Chemical 2629] is; Ar is [Chemical 2630] 、 [Chemical 2631] 、 [Chemical 2632] 、 [Chemical 2633] or [Chemical 2634] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2635] (XVII) (In the formula, L-Ar is [Chemical 2636] 、 [Chemical 2637] or [Chemical 2638] is; Ar is [Chemical 2639] 、 [Chemical 2640] 、 [Chemical 2641] 、 [Chemical 2642] or [Chemical 2643] with the proviso that L-Ar is [Chemical 2644] When , Ar is [Chemical 2645] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2646] (XVIII) (In the formula, L-Ar is [Chemical 2647] 、 [Chemical 2648] or [Chemical 2649] is; Ar is [Chemical 2650] 、 [Chemical 2651] 、 [Chemical 2652] 、 [Chemical 2653] or [Chemical 2654] with the proviso that L-Ar is [Chemical 2655] when Ar is [Chemical 2656] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2657] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2658] 、 [Chemical 2659] 、 [Chemical 2660] 、 [Chemical 2661] or [Chemical 2662] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2663] (XX) (In the formula, L-Ar is [Chemical 2664] 、 [Chemical 2665] or [Chemical 2666] is; Ar is [Chemical 2667] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2668] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

19. A method of treating a disease or condition in which interleukin-1 beta (IL1β) levels are elevated, comprising: (a) Formula (IX) [Chemical 2669] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2670] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2671] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2672] (XII) (In the formula, L-Ar is [Chemical 2673] 、 [Chemical 2674] or [Chemical 2675] is; Ar is [Chemical 2676] 、 [Chemical 2677] 、 [Chemical 2678] 、 [Chemical 2679] or [Chemical 2680] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2681] (XIII) (In the formula, L-Ar is [Chemical 2682] 、 [Chemical 2683] or [Chemical 2684] is; Ar is [Chemical 2685] 、 [Chemical 2686] 、 [Chemical 2687] 、 [Chemical 2688] or [Chemical 2689] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2690] (XIV) (In the formula, L-Ar is [Chemical 2691] 、 [Chemical 2692] or [Chemical 2693] is; Ar is [Chemical 2694] 、 [Chemical 2695] 、 [Chemical 2696] 、 [Chemical 2697] or [Chemical 2698] with the proviso that L-Ar is [Chemical 2699] when Ar is [Chemical 2700] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2701] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2702] 、 [Chemical 2703] or [Chemical 2704] is; Ar is [Chemical 2705] 、 [Chemical 2706] 、 [Chemical 2707] 、 [Chemical 2708] or [Chemical 2709] with the proviso that L-Ar is [Chemical 2710] When , Ar is [Chemical 2711] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2712] (XVI) (In the formula, L-Ar is [Chemical 2713] 、 [Chemical 2714] or [Chemical 2715] is; Ar is [Chemical 2716] 、 [Chemical 2717] 、 [Chemical 2718] 、 [Chemical 2719] or [Chemical 2720] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2721] (XVII) (In the formula, L-Ar is [Chemical 2722] 、 [Chemical 2723] or [Chemical 2724] is; Ar is [Chemical 2725] 、 [Chemical 2726] 、 [Chemical 2727] 、 [Chemical 2728] or [Chemical 2729] with the proviso that L-Ar is [Chemical 2730] when Ar is [Chemical 2731] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2732] (XVIII) (In the formula, L-Ar is [Chemical 2733] 、 [Chemical 2734] or [Chemical 2735] is; Ar is [Chemical 2736] 、 [Chemical 2737] 、 [Chemical 2738] 、 [Chemical 2739] or [Chemical 2740] with the proviso that L-Ar is [Chemical 2741] when Ar is [Chemical 2742] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2743] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2744] 、 [Chemical 2745] 、 [Chemical 2746] 、 [Chemical 2747] or [Chemical 2748] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2749] (XX) (In the formula, L-Ar is [Chemical 2750] 、 [Chemical 2751] or [Chemical 2752] is; Ar is [Chemical 2753] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2754] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

20. Helper T cells (T h ) A method of treating a disease or condition with elevated levels, comprising, in a subject in need thereof, (a) Formula (IX) [Chemical 2755] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2756] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2757] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2758] (XII) (In the formula, L-Ar is [Chemical 2759] 、 [Chemical 2760] or [Chemical 2761] is; Ar is [Chemical 2762] 、 [Chemical 2763] 、 [Chemical 2764] 、 [Chemical 2765] or [Chemical 2766] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2767] (XIII) (In the formula, L-Ar is [Chemical 2768] 、 [Chemical 2769] or [Chemical 2770] is; Ar is [Chemical 2771] 、 [Chemical 2772] 、 [Chemical 2773] 、 [Chemical 2774] or [Chemical 2775] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2776] (XIV) (In the formula, L-Ar is [Chemical 2777] 、 [Chemical 2778] or [Chemical 2779] is; Ar is [Chemical 2780] 、 [Chemical 2781] 、 [Chemical 2782] 、 [Chemical 2783] or [Chemical 2784] with the proviso that L-Ar is [Chemical 2785] When , Ar is [Chemical 2786] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2787] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2788] 、 [Chemical 2789] or [Chemical 2790] is; Ar is [Chemical 2791] 、 [Chemical 2792] 、 [Chemical 2793] 、 [Chemical 2794] or [Chemical 2795] with the proviso that L-Ar is [Chemical 2796] when Ar is [Chemical 2797] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2798] (XVI) (In the formula, L-Ar is [Chemical 2799] 、 [Chemical 2800] or [Chemical 2801] is; Ar is [Chemical 2802] 、 [Chemical 2803] 、 [Chemical 2804] 、 [Chemical 2805] or [Chemical 2806] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2807] (XVII) (In the formula, L-Ar is [Chemical 2808] 、 [Chemical 2809] or [Chemical 2810] is; Ar is [Chemical 2811] 、 [Chemical 2812] 、 [Chemical 2813] 、 [Chemical 2814] or [Chemical 2815] with the proviso that L-Ar is [Chemical 2816] When , Ar is [Chemical 2817] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2818] (XVIII) (In the formula, L-Ar is [Chemical 2819] 、 [Chemical 2820] or [Chemical 2821] is; Ar is [Chemical 2822] 、 [Chemical 2823] 、 [Chemical 2824] 、 [Chemical 2825] or [Chemical 2826] with the proviso that L-Ar is [Chemical 2827] when Ar is [Chemical 2828] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2829] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2830] 、 [Chemical 2831] 、 [Chemical 2832] 、 [Chemical 2833] or [Chemical 2834] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2835] (XX) During the ceremony, L-Ar is [Chemical 2836] 、 [Chemical 2837] or [Chemical 2838] is; Ar is [Chemical 2839] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2840] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

21. Regulatory T cells (T reg ) is reduced or inhibited, comprising: (a) Formula (IX) [Chemical 2841] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2842] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2843] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2844] (XII) (In the formula, L-Ar is [Chemical 2845] 、 [Chemical 2846] or [Chemical 2847] is; Ar is [Chemical 2848] 、 [Chemical 2849] 、 [Chemical 2850] 、 [Chemical 2851] or [Chemical 2852] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2853] (XIII) (In the formula, L-Ar is [Chemical 2854] 、 [Chemical 2855] or [Chemical 2856] is; Ar is [Chemical 2857] 、 [Chemical 2858] 、 [Chemical 2859] 、 [Chemical 2860] or [Chemical 2861] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2862] (XIV) (In the formula, L-Ar is [Chemical 2863] 、 [Chemical 2864] or [Chemical 2865] is; Ar is [Chemical 2866] 、 [Chemical 2867] 、 [Chemical 2868] 、 [Chemical 2869] or [Chemical 2870] with the proviso that L-Ar is [Chemical 2871] when Ar is [Chemical 2872] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2873] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2874] 、 [Chemical 2875] or [Chemical 2876] is; Ar is [Chemical 2877] 、 [Chemical 2878] 、 [Chemical 2879] 、 [Chemical 2880] or [Chemical 2881] with the proviso that L-Ar is [Chemical 2882] When , Ar is [Chemical 2883] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2884] (XVI) (In the formula, L-Ar is [Chemical 2885] 、 [Chemical 2886] or [Chemical 2887] is; Ar is [Chemical 2888] 、 [Chemical 2889] 、 [Chemical 2890] 、 [Chemical 2891] or [Chemical 2892] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 is independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2893] (XVII) (In the formula, L-Ar is [Chemical 2894] 、 [Chemical 2895] or [Chemical 2896] is; Ar is [Chemical 2897] 、 [Chemical 2898] 、 [Chemical 2899] 、 [Chemical 2900] or [Chemical 2901] with the proviso that L-Ar is [Chemical 2902] When , Ar is [Chemical 2903] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2904] (XVIII) (In the formula, L-Ar is [Chemical 2905] 、 [Chemical 2906] or [Chemical 2907] is; Ar is [Chemical 2908] 、 [Chemical 2909] 、 [Chemical 2910] 、 [Chemical 2911] or [Chemical 2912] with the proviso that L-Ar is [Chemical 2913] when Ar is [Chemical 2914] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 2915] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 2916] 、 [Chemical 2917] 、 [Chemical 2918] 、 [Chemical 2919] or [Chemical 2920] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 2921] (XX) (In the formula, L-Ar is [Chemical 2922] 、 [Chemical 2923] or [Chemical 2924] is; Ar is [Chemical 2925] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 2926] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

22. A method of reversing established non-alcoholic steatohepatitis (NASH), comprising: (a) Formula (IX) [Chemical 2927] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 2928] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 2929] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 2930] (XII) (In the formula, L-Ar is [Chemical 2931] 、 [Chemical 2932] or [Chemical 2933] is; Ar is [Chemical 2934] 、 [Chemical 2935] 、 [Chemical 2936] 、 [Chemical 2937] or [Chemical 2938] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 2939] (XIII) (In the formula, L-Ar is [Chemical 2940] 、 [Chemical 2941] or [Chemical 2942] is; Ar is [Chemical 2943] 、 [Chemical 2944] 、 [Chemical 2945] 、 [Chemical 2946] or [Chemical 2947] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 2948] (XIV) (In the formula, L-Ar is [Chemical 2949] 、 [Chemical 2950] or [Chemical 2951] is; Ar is [Chemical 2952] 、 [Chemical 2953] 、 [Chemical 2954] 、 [Chemical 2955] or [Chemical 2956] with the proviso that L-Ar is [Chemical 2957] when Ar is [Chemical 2958] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 2959] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 2960] 、 [Chemical 2961] or [Chemical 2962] is; Ar is [Chemical 2963] 、 [Chemical 2964] 、 [Chemical 2965] 、 [Chemical 2966] or [Chemical 2967] with the proviso that L-Ar is [Chemical 2968] When , Ar is [Chemical 2969] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 2970] (XVI) (In the formula, L-Ar is [Chemical 2971] 、 [Chemical 2972] or [Chemical 2973] is; Ar is [Chemical 2974] 、 [Chemical 2975] 、 [Chemical 2976] 、 [Chemical 2977] or [Chemical 2978] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 2979] (XVII) (In the formula, L-Ar is [Chemical 2980] 、 [Chemical 2981] or [Chemical 2982] is; Ar is [Chemical 2983] 、 [Chemical 2984] 、 [Chemical 2985] 、 [Chemical 2986] or [Chemical 2987] with the proviso that L-Ar is [Chemical 2988] When , Ar is [Chemical 2989] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 2990] (XVIII) (In the formula, L-Ar is [Chemical 2991] 、 [Chemical 2992] or [Chemical 2993] is; Ar is [Chemical 2994] 、 [Chemical 2995] 、 [Chemical 2996] 、 [Chemical 2997] or [Chemical 2998] with the proviso that L-Ar is [Chemical 2999] when Ar is [chemical 3000] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 3001] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl; or 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 3002] 、 [Chemical 3003] 、 [Chemical 3004] 、 [Chemical 3005] or [Chemical 3006] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 3007] (XX) (In the formula, L-Ar is [Chemical 3008] 、 [chemical 3009] or [Chemical 3010] is; Ar is [Chemical 3011] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 3012] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 alkyl)) or a pharmaceutically acceptable salt thereof.

23. A method of reducing fibrosis gene expression, comprising, in a subject in need thereof, comprising: (a) Formula (IX) [Chemical 3013] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 3014] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 3015] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 3016] (XII) (In the formula, L-Ar is [Chemical 3017] 、 [Chemical 3018] or [Chemical 3019] is; Ar is [Chemical 3020] 、 [Chemical 3021] 、 [Chemical 3022] 、 [Chemical 3023] or [Chemical 3024] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 3025] (XIII) (In the formula, L-Ar is [Chemical 3026] 、 [Chemical 3027] or [Chemical 3028] is; Ar is [Chemical 3029] 、 [Chemical 3030] 、 [Chemical 3031] 、 [Chemical 3032] or [Chemical 3033] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 3034] (XIV) (In the formula, L-Ar is [Chemical 3035] 、 [Chemical 3036] or [Chemical 3037] is; Ar is [Chemical 3038] 、 [Chemical 3039] 、 [Chemical 3040] 、 [Chemical 3041] or [Chemical 3042] with the proviso that L-Ar is [Chemical 3043] when Ar is [Chemical 3044] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 3045] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 3046] 、 [Chemical 3047] or [Chemical 3048] is; Ar is [Chemical 3049] 、 [Chemical 3050] 、 [Chemical 3051] 、 [Chemical 3052] or [Chemical 3053] with the proviso that L-Ar is [Chemical 3054] when Ar is [Chemical 3055] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 3056] (XVI) (In the formula, L-Ar is [Chemical 3057] 、 [Chemical 3058] or [Chemical 3059] is; Ar is [Chemical 3060] 、 [Chemical 3061] 、 [Chemical 3062] 、 [Chemical 3063] or [Chemical 3064] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 3065] (XVII) (In the formula, L-Ar is [Chemical 3066] 、 [Chemical 3067] or [Chemical 3068] is; Ar is [Chemical 3069] 、 [Chemical 3070] 、 [Chemical 3071] 、 [Chemical 3072] or [Chemical 3073] with the proviso that L-Ar is [Chemical 3074] when Ar is [Chemical 3075] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 3076] (XVIII) (In the formula, L-Ar is [Chemical 3077] 、 [Chemical 3078] or [Chemical 3079] is; Ar is [Chemical 3080] 、 [Chemical 3081] 、 [Chemical 3082] 、 [Chemical 3083] or [Chemical 3084] with the proviso that L-Ar is [Chemical 3085] when Ar is [Chemical 3086] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 3087] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 3088] 、 [Chemical 3089] 、 [Chemical 3090] 、 [Chemical 3091] or [Chemical 3092] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 3093] (XX) (In the formula, L-Ar is [Chemical 3094] 、 [Chemical 3095] or [Chemical 3096] is; Ar is [Chemical 3097] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 3098] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

24. A method of treating dermatofibrosis, comprising: (a) Formula (IX) [Chemical 3099] (IX) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -OH, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), where t is 0 or 1; C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; L. 1 is CR 23 or N; L. 2 is CH or N; L. 1 or L 2 at least one of is N; R. 23 is H or C 1 ~C 4 is a straight or branched chain alkyl) or a pharmaceutically acceptable salt thereof; or (b) Formula (X): [Chemical 3100] (X) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; L. 3 is C(R 60 ) 2 , O or NR 50 is; Each R 60 are independently H, -OH, -CN, -O t -(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), or -C(O)-N(R 601 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; Each R 50 are independently H, -C(O)-O t -(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 3 ~C 5 cyclic alkyl), -C optionally containing an oxygen or nitrogen heteroatom 3 ~C 5 Cyclic alkyl, -C(O)-N(R 501 ) 2 , C 1 ~C 4 is a straight or branched chain alkyl, where t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; n is 1, 2 or 3; m is 1 or 2; R. 21 is H, halogen, C 1 ~C 4 straight or branched chain alkyl, C 3 ~C 5 cycloalkyl, where C 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; Each R 26 are independently -OH, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 straight or branched chain alkyl), -C(O)-O t -(C 1 ~C 4 alkyl), or -C(O)-N(R 501 ) 2 and in this case t is 0 or 1, C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; s is 0, 1 or 2; Each R 601 and R 501 is independently H or C 1 ~C 4 is a straight or branched chain alkyl; where R 26 , R 60 , R 50 , R 501 and R 601 are optionally linked to form a ring, where R 26 , R 60 , R 50 , R 501 and R 601 two of the two R 26 , two R 60 , two R 50 , two R 501 or two R 601 or a pharmaceutically acceptable salt thereof; or (c) Formula (VI-J) [Chemical 3101] (VI-J) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)-R 351 , -C(O)-NHR 351 , -C(O)-O-R 351 or S(O) 2 R. 351 is; R. 351 is C 1 ~C 6 a straight or branched chain alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (d) Formula (XII): [Chemical 3102] (XII) (In the formula, L-Ar is [Chemical 3103] 、 [Chemical 3104] or [Chemical 3105] is; Ar is [Chemical 3106] 、 [Chemical 3107] 、 [Chemical 3108] 、 [Chemical 3109] or [Chemical 3110] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 6 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; Each R 241 is independently H or C 1 ~C 2 is an alkyl; R. 25 is halogen, -CN, -(C 1 ~C 4 alkyl)-CN,C 1 ~C 2 alkyl or cyclopropyl) or a pharmaceutically acceptable salt thereof; or (e) Formula (XIII): [Chemical 3111] (XIII) (In the formula, L-Ar is [Chemical 3112] 、 [Chemical 3113] or [Chemical 3114] is; Ar is [Chemical 3115] 、 [Chemical 3116] 、 [Chemical 3117] 、 [Chemical 3118] or [Chemical 3119] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; Each R 24 and R 25 are independently H, halogen, -CN, -(C 1 ~C 4 alkyl)-CN, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; each u is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (f) Formula (XIV): [Chemical 3120] (XIV) (In the formula, L-Ar is [Chemical 3121] 、 [Chemical 3122] or [Chemical 3123] is; Ar is [Chemical 3124] 、 [Chemical 3125] 、 [Chemical 3126] 、 [Chemical 3127] or [Chemical 3128] with the proviso that L-Ar is [Chemical 3129] When , Ar is [Chemical 3130] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl) t -N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O t -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O t -(4- to 6-membered heterocycle) or -(C 1 ~C 4 alkyl) t -O-(C 1 ~C 4 alkyl), where each t is independently 0 or 1; Each R 241 is independently H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (g) Formula (XV): [Chemical 3131] (XV) (In the formula, L. 3 is -CH 2 -, -CHR 50 -, -O-, -NR 50 -, -NC(O)R 50 -or- NC(O)OR 50 - and in this case R 50 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; n is 1, 2 or 3; m is 1 or 2, provided that n+m≧3; L-Ar is [Chemical 3132] 、 [Chemical 3133] or [Chemical 3134] is; Ar is [Chemical 3135] 、 [Chemical 3136] 、 [Chemical 3137] 、 [Chemical 3138] or [Chemical 3139] with the proviso that L-Ar is [Chemical 3140] when Ar is [Chemical 3141] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 alkyl) or a pharmaceutically acceptable salt thereof; or (h) Formula (XVI): [Chemical 3142] (XVI) (In the formula, L-Ar is [Chemical 3143] 、 [Chemical 3144] or [Chemical 3145] is; Ar is [Chemical 3146] 、 [Chemical 3147] 、 [Chemical 3148] 、 [Chemical 3149] or [Chemical 3150] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 and R 25 are independently H, -C 1 ~C 4 is alkyl or halogen) or a pharmaceutically acceptable salt thereof; or (i) Formula (XVII): [Chemical 3151] (XVII) (In the formula, L-Ar is [Chemical 3152] 、 [Chemical 3153] or [Chemical 3154] is; Ar is [Chemical 3155] 、 [Chemical 3156] 、 [Chemical 3157] 、 [Chemical 3158] or [Chemical 3159] with the proviso that L-Ar is [Chemical 3160] When , Ar is [Chemical 3161] not; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is H, C 1 ~C 4 Alkyl, -(C 1 ~C 4 Alkyl)-OH, -(C 1 ~C 4 alkyl)-N(R 241 ) 2 , -(C 1 ~C 4 alkyl) t -O u -(C 3 ~C 5 cycloalkyl), -(C 1 ~C 4 alkyl) t -O u -(4- to 6-membered heterocycle) or -(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), where t is 0 or 1; u is 0 or 1; However, when u is 1, t is 1; R. 241 is H or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (j) Formula (XVIII): [Chemical 3162] (XVIII) (In the formula, L-Ar is [Chemical 3163] 、 [Chemical 3164] or [Chemical 3165] is; Ar is [Chemical 3166] 、 [Chemical 3167] 、 [Chemical 3168] 、 [Chemical 3169] or [Chemical 3170] with the proviso that L-Ar is [Chemical 3171] When , Ar is [Chemical 3172] not; L. 2 -NHR 35 or -C(O)NHR 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 is cycloalkyl, 4- to 6-membered heterocycle, aryl or heteroaryl; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 35 is -C(O)R 351 , -C(O)NHR 351 , C(O)OR 351 or S(O) 2 R. 351 and in this case R 351 is C 1 ~C 6 Alkyl, C 3 ~C 5 cycloalkyl, 4-6 membered heterocycle, aryl or heteroaryl) or a pharmaceutically acceptable salt thereof; or (k) Formula (XIX): [Chemical 3173] (XIX) (In the formula, Each W, X, Y and Z is independently -N- or -CR 26 -, provided that no more than two of W, X, Y and Z are -N-; Each R 26 are independently H, C 1 ~C 4 Alkyl, -O-(C 1 ~C 4 alkyl), -N(R 27 ) 2 , -S(O) 2 -(C 1 ~C 4 alkyl), or -C(O)-(C 1 ~C 4 alkyl); Each R 27 is independently H or C 1 ~C 4 is alkyl, or R 27 are both C 1 ~C 4 Alkyl, which together with the N to which they are attached are linked together to form a 3- to 6-membered ring in which the ring optionally has one oxygen atom as one of the ring members. including Ar is [Chemical 3174] 、 [Chemical 3175] 、 [Chemical 3176] 、 [Chemical 3177] or [Chemical 3178] is; Het is 5-6 membered heteroaryl; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle), -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 11 is H or -CH 3 is; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is alkyl) or a pharmaceutically acceptable salt thereof; or (l) Formula (XX): [Chemical 3179] (XX) (In the formula, L-Ar is [Chemical 3180] 、 [Chemical 3181] or [Chemical 3182] is; Ar is [Chemical 3183] is; R. 1 is H, -CN, halogen, C 1 ~C 4 Alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(4- to 6-membered heterocycle) or -O-(C 1 ~C 4 alkyl), where R 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently hydrogen, halogen or C 1 ~C 4 is an alkyl; R. 3 is H or F; R. 21 is H, halogen, C 1 ~C 4 Alkyl, C 3 ~C 5 is cycloalkyl or a 4- to 6-membered heterocyclic ring; R. 22 is H, halogen or C 1 ~C 2 is an alkyl; R. 24 is -O-(C 1 ~C 4 alkyl), -O-(C 1 ~C 4 Alkyl)-O-(C 1 ~C 4 alkyl), -O-(C 3 ~C 5 cycloalkyl), or -O-(4- to 6-membered heterocycle), where R 24 is optionally substituted with one or more hydroxyls or halogens; R. 25 is H, halogen, C 1 ~C 4 alkyl or C 3 ~C 5 cycloalkyl, where R 25 is optionally substituted with one or more halogens) or a pharmaceutically acceptable salt thereof; or (m) Formula (XI): [Chemical 3184] (XI) (In the formula, R. 1 is H, -CN, halogen, C 1 ~C 4 straight or branched chain alkyl, -O-(C 3 ~C 5 cycloalkyl), -O-(C 1 ~C 4 straight or branched chain alkyl), where C. 3 ~C 5 cycloalkyl optionally includes an oxygen or nitrogen heteroatom; R. 1 is not H, -CN, or halogen, then R 1 is optionally substituted with one or more halogens; Each R 2 is independently H, halogen or C 1 ~C 4 is a straight or branched chain alkyl; R. 3 is H, -OH or halogen; R. 21 is cyclobutyl, azetidin-1-yl, or cyclopropyl; R. 22 is H, halogen, C 1 ~C 2 is an alkyl; R. 351 is C 1 ~C 2 alkyl or C 2 -O-(C 1 or C 2 Alkyl)) or a pharmaceutically acceptable salt thereof.

25. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (IX), (X), (XII), (XIV), (XV) or (XX).

26. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (IX).

27. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (X).

28. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has formula (XII).

29. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (XIV).

30. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (XV).

31. 25. The method of any one of claims 13-24, wherein the fatty acid synthase inhibitor has the formula (XX).

32. The fatty acid synthase inhibitor is [Chemical 3185] 25. The method of any one of claims 13-24, selected from

33. The fatty acid synthase inhibitor is [Chemical 3186] 25. The method of any one of claims 13-24, selected from

34. said disease or condition is Familial Mediterranean Fever (FMF), septic arthritis, pyoderma gangrenosum, acne (PAPA), cryopyrin-associated periodic fever syndrome (CAPS), hyper-IgD syndrome (HIDS), adult and juvenile still disease, Schnitzler syndrome, TNF receptor-associated periodic syndrome (TRAPS), Blau syndrome, Sweet syndrome, IL-1 receptor antagonist deficiency (DIRA), recurrent idiopathic pericarditis, macrophage activation syndrome (MAS) , urticaria vasculitis, antisynthetic enzyme syndrome, recurrent chondritis, Behcet's disease, Erdheim-Chester syndrome (histiocytosis), synovitis, acne, pustulosis, ossification, osteitis (SAPHO), Rheumatoid arthritis, periodic fever, aphthous stomatitis, pharyngitis, lymphadenitis syndrome (PFAPA), urate crystalline arthritis (gout), type 2 diabetes, smoldering multiple myeloma, post-myocardial infarction heart failure, osteoarthritis, transfusion-related 20. The method of claim 19 selected from acute lung injury, ventilator-induced lung injury, pulmonary fibrosis including idiopathic, chronic obstructive pulmonary disease, and asthma.

35. 22. The method of claim 20 or 21, wherein said disease or condition is selected from psoriasis, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, inflammatory bowel disease, asthma, neoplasia and transplant rejection.

36. said elevated helper T cells h 1, T. h 2, T. h 9 or T h 21. The method of claim 20, which is 17.

37. said elevated helper T cells 17 37. The method of claim 36, wherein

38. T. reg 22. The method of claim 21, wherein the cells are suppressed.

39. 14. The method of claim 13, wherein treating non-alcoholic steatohepatitis comprises reversing at least one symptom of established non-alcoholic steatohepatitis.

40. 14. The method of claim 13, wherein treating nonalcoholic steatohepatitis comprises preventing progression of at least one symptom of nonalcoholic steatohepatitis.

41. wherein said condition is selected from elevated AST levels, elevated ALT levels, elevated liver triglyceride levels, elevated cholesterol levels, liver steatosis, hepatitis, liver ballooning, liver fibrosis and NAFLD activity score.

41. The method of paragraphs 39 or 40.

Images